The Relevance of Transcription Factors in Gastric and Colorectal Cancer Stem Cells Identification and Eradication

Diana Pádua1,2, Paula Figueira1,2, Inês Ribeiro1,2, Raquel Almeida1,2,3,4 and Patricia Mesquita1,2*

1 i3S – Institute for Research and Innovation in Health, University of Porto, Porto, Portugal, 2 Institute of Molecular Pathology and Immunology, University of Porto, Porto, Portugal, 3 Faculty of Medicine, University of Porto, Porto, Portugal, 4 Department of Biology, Faculty of Sciences, University of Porto, Porto, Portugal

OPEN ACCESS

Edited by:
Susana Solá,
University of Lisbon, Portugal

Reviewed by:
Asfar S. Azmi,
Wayne State University Karmanos Cancer Institute, United States
borhaneguzhe,
German Cancer Research Center, Germany

*Correspondence:
Patrícia Mesquita
pmesquita@ipatimup.pt

Specialty section:
This article was submitted to Stem Cell Research, a section of the journal Frontiers in Cell and Developmental Biology

Received: 20 March 2020
Accepted: 11 May 2020
Published: 18 June 2020

Citation:
Pádua D, Figueira P, Ribeiro I, Almeida R and Mesquita P (2020) The Relevance of Transcription Factors in Gastric and Colorectal Cancer Stem Cells Identification and Eradication. Front. Cell Dev. Biol. 8:442. doi: 10.3389/fcell.2020.00442

Gastric and colorectal cancers have a high incidence and mortality worldwide. The presence of cancer stem cells (CSCs) within the tumor mass has been indicated as the main reason for tumor relapse, metastasis and therapy resistance, leading to poor overall survival. Thus, the elimination of CSCs became a crucial goal for cancer treatment. The identification of these cells has been performed by using cell-surface markers, a reliable approach, however it lacks specificity and usually differs among tumor type and in some cases even within the same type. In theory, the ideal CSC markers are those that are required to maintain their stemness features. The knowledge that CSCs exhibit characteristics comparable to normal stem cells that could be associated with the expression of similar transcription factors (TFs) including SOX2, OCT4, NANOG, KLIF4 and c-Myc, and signaling pathways such as the Wnt/β-catenin, Hedgehog (Hh), Notch and PI3K/AKT/mTOR directed the attention to the use of these similarities to identify and target CSCs in different tumor types. Several studies have demonstrated that the abnormal expression of some TFs and the dysregulation of signaling pathways are associated with tumorigenesis and CSC phenotype. The disclosure of common and appropriate biomarkers for CSCs will provide an incredible tool for cancer prognosis and treatment. Therefore, this review aims to gather the new insights in gastric and colorectal CSC identification specially by using TFs as biomarkers and divulge promising drugs that have been found and tested for targeting these cells.

Keywords: gastric cancer, colorectal cancer, transcription factors, cancer stem cells, signaling pathways, targeted therapy

INTRODUCTION

Gastrointestinal malignancies are listed among the major causes of cancer death worldwide, being associated with environmental and genetic risk factors such as older age, chronic inflammation, family history, smoking, dietary patterns, overweight and physical inactivity, as well as gut microbiota (Lochhead and El-Omar, 2008; Mattiuzzi et al., 2019). Gastric cancer (GC) and colorectal cancer (CRC) are among the top five most incident and deadly cancers worldwide
As surgical techniques improve, as well as radiotherapy, chemotherapy and neoadjuvant therapies, the 5-year survival rate can reach up to 95% for early GC and 90% for localized CRC (Song et al., 2017; Sonbol et al., 2019). However, most patients have advanced-stage disease at diagnosis and so the best surgical window is missed (Song et al., 2017; Bray et al., 2018). They develop recurrent loco-regional disease or distant metastases with consequent decrease in survival. The heterogeneity of cancer at molecular, histological and phenotypic levels plays an important role in therapy resistance and tumor recurrence, being cancer stem cells (CSCs) among the major causative factors of cancer heterogeneity and treatment failure (Iseghohi, 2016; Gullo et al., 2018). The CSC model of tumor progression hypothesizes that a small subpopulation of cancer cells that display stem-like properties sustains tumor growth, metastasis, relapse and resistance to chemotherapy (Iseghohi, 2016). CSCs can undergo symmetric and asymmetric divisions, having the ability to give rise to all the different types of cancer cells within the tumor (Marjanovic et al., 2013). The origin of CSCs is still unclear and controversial (Dalerba et al., 2007a; Brunner et al., 2012). Various hypotheses suggest that depending on the tumor type, CSCs might be derived from adult stem cells, adult progenitor cells that underwent mutations, or differentiated cells that gained stem-like properties through dedifferentiation (Basu et al., 2016; Phi et al., 2018). A large number of studies demonstrate that CSCs share biomarkers with normal stem cells, thus specific markers for their identification have been explored in recent years. It is known that some transcription factors (TFs) can be re-expressed or reactivated in CSCs, playing a crucial role in the reprogramming of these cells. This review aims to provide a better understanding on how TFs associated with gastric and colorectal CSCs phenotype can be used for CSCs identification, characterization and targeted therapy.

THE CHALLENGES OF CANCER STEM CELL IDENTIFICATION

The identification of normal stem cells is now an easy process due to their well-recognized set of biomarkers whereas the identification of CSCs is a challenging task resulting from their complex phenotype, that differs from one tumor to another (Pattabiraman and Weinberg, 2014). Additionally, CSCs represent a very small percentage of tumor cells within the total tumor mass making even harder their detection in heterogeneous tumors (Kim Y. et al., 2009). The use of different combinations of cell-surface markers has been the main strategy to identify CSCs in several tumor types (Magee et al., 2012). The cell-surface markers are chosen according to their expression and relevance in the tumor type allowing the separation of CSCs from non-CSCs (Pattabiraman and Weinberg, 2014). In GC and CRC, the list of cell-surface markers capable of identifying CSCs is growing (Table 1). This means that the interest in gastric and colorectal CSCs identification and targeting is rising but also means that the already used markers are not uniformly advantageous for CSCs detection. In particular, inconsistencies remain concerning which cell-surface marker may be the ideal marker to identify gastric and colorectal CSCs from cell lines and primary tumors (Takaishi et al., 2009; Zhang et al., 2011; Jiang Y. et al., 2012; Rocco et al., 2012; Wakamatsu et al., 2012; Brungs et al., 2016).

Gastric Cancer

Several cell-surface markers have emerged for gastric CSC identification. The transmembrane glycoprotein CD44 was the first described cell-surface marker used in gastric CSC identification. Takaishi et al. (2009) and his collaborators analyzed a panel of six GC cell lines and in three of them – NCI-N87, MKN-45 and MKN-74 – a small CD44+ cell subpopulation displayed CSC features such as self-renewal, asymmetric division, spheroid colony formation, and in vivo tumorigenic ability. They also observed that the CD44+ subpopulation had a higher resistance to anticancer drugs when compared to CD44− cells (Takaishi et al., 2009). However, in the other three cell lines – AGS, Kato III and MKN28 – the CD44 cell-surface marker was not able to mark cells with stem cell properties (Takaishi et al., 2009). Clinically, CD44+ cancer cells at the invasive GC front are associated with poor patient survival (Nosrati et al., 2014; Kodama et al., 2017). Later, Zhang et al. (2011) combined CD44 with CD24, a signal transducer, and successfully detected a CD44+CD24+ cellular subpopulation with CSCs characteristics, such as the capability to self-renew and to originate differentiated progeny (Zhang et al., 2011). Additionally, they showed that CD44+CD24+ cells had higher ability to form tumors when injected into immunodeficient mice, compared to the CD44−CD24− cells (Zhang et al., 2011). The CD54 cell-surface marker, also known as ICAM-1 (intercellular adhesion molecule 1), was combined with CD44 to isolate gastric CSCs from tumor tissues and peripheral blood of patients with GC (Chen et al., 2012). The CD44+CD54+ cells exhibited in vitro and in vivo self-renewal ability, formed gastric tumorspheres and originated tumors similar to the original human tumor when injected into immunodeficient mice (Chen et al., 2012). The epithelial cell adhesion molecule (Epcam) has also been used in combination with CD44 to mark gastric CSCs. The small EpcAM+/CD44+ subpopulation isolated from primary human GC tissues was more resistant to anticancer drugs including 5-fluorouracil (5-FU), doxorubicin, vinblastine and paclitaxel, when compared with EpcAM−/CD44−, EpcAM−/CD44+ and EpcAM+/CD44− cells (Brabletz et al., 2005; Han et al., 2011). It also showed capacity to form sphere-like structures in serum free conditions and greater ability to originate tumors in immunocompromised mice (Han et al., 2011). The tumors formed after inoculation of the EpcAM+/CD44+ cells recapitulated the heterogeneous morphology and phenotype present in the original gastric tumor (Han et al., 2011). Moreover, Fukamachi et al. (2013) identified another potential gastric CSC marker, the CD49f, an integrin α6 (ITGA6) that is a subunit of laminin receptors. Their work showed that CD49f+ cells from GC originated tumors when subcutaneously injected into immunodeficient mice, while CD49f− cells did not (Fukamachi et al., 2013). They also demonstrated that some of the CD49f+ sphere-forming cells were more resistant to doxorubicin, 5-FU and doxifluridine than the other GC cells studied (Fukamachi et al., 2013). Another cell-surface marker identified as a gastric
**TABLE 1 |** Cancer stem cell (CSC) biomarkers for gastric and colorectal cancer.

| CSCs biomarkers | Gastric Cancer | References | Colorectal Cancer | References |
|-----------------|----------------|------------|-------------------|------------|
| CD44            |                | Takashii et al., 2009; Zhang X. et al., 2016 | Du et al., 2008; Huang et al., 2015 |
| CD44 combined with CD24 | Zhang et al., 2011 | — | — |
| CD44 combined with CD54 | Chen et al., 2012 | — | — |
| CD44 combined with EpCAM | Han et al., 2011 | — | — |
| CD44 combined with CD133 | — | Dalerba et al., 2007b |
| CD49f           | Fukamachi et al., 2013 | — | — |
| CD71            |                | — | — |
| CD90            | Ohikuma et al., 2012 | — | — |
| CD133           |                | Fukamachi et al., 2011; Zhang X. et al., 2016 | O’Brien et al., 2007; Ricci-Vitiani et al., 2007; Huang et al., 2015 |
| CD133 combined with CD166 | — | — | Dalerba et al., 2007b |
| CD184 (CXCR4)   | Fujita et al., 2015 | — | — |
| CD200           | — | Zhang S.S. et al., 2016 | — |
| Lgr5            | Gong et al., 2016 | — | — |
| Lgr5 combined with EpCAM | — | Kemper et al., 2012 | — |
| Lgr5 combined with EpCAM and CD44 | — | Leng et al., 2018 | — |
| ALDH            | Zhi et al., 2011 | — | Huang et al., 2009 |
| SOX2            | Pádua et al., 2020 | — | Takeda et al., 2018 |

The table contains some of the most reported CSCs markers used for both tumor types.

The CD71 transferrin receptor is one of the CSC markers. It has been demonstrated that the CD71− subpopulation from the MKN-1 GC cell line displayed CSC features, contrary to CD71+ cells. CD71− cells were more resistant to 5-FU than CD71+, had higher tumorigenic ability and were mostly present in the invasive front of the tumor (Ohkuma et al., 2012). The cell-surface glycoprotein CD90 (Thy-1) appeared as a potential gastric CSC marker since it was capable of identifying a small population with in vivo tumorigenic and self-renewal ability (Jiang J. et al., 2012). Additionally, 25% of the gastric primary tumors possessed higher expression of erb-b2 receptor tyrosine kinase 2 (HER2), which was correlated with the higher expression of CD90 (Jiang J. et al., 2012). CD133 (prominin-1), a pentaspan transmembrane glycoprotein, is described as a gastric CSC marker due to the fact that its expression is positively correlated with tumor aggressiveness in GC patients (Fukamachi et al., 2011; Lee et al., 2012; Wakamatsu et al., 2012; Hashimoto et al., 2014; Nosrati et al., 2014). Zhao et al. showed that the frequency of CD133+ in gastric primary tumors samples was higher than CD133− cells and CD133 was associated with poor prognosis in GC (Zhao et al., 2010). Also, spheroid cells from GC cell lines and primary GC tissues presented CD133 expression and displayed several features of CSCs (Zhang X. et al., 2016). New cell-surface markers have emerged in the study of gastric CSCs and demonstrated to be able to mark a small population in GC with stem-like features, specifically Lgr5 (leucine-rich repeat-containing G-protein coupled receptor 5) and CXCR4 (C-X-C chemokine receptor type 4) also known as CD184 (Fujita et al., 2015; Gong et al., 2016). Also, the intracellular enzyme aldehyde dehydrogenase (ALDH) has been used to identify gastric CSCs (Zhi et al., 2011; Wakamatsu et al., 2012). Zhi et al. (2011) were able to divide NCI-N87 and SNU-1 GC cell lines into ALDH+ and ALDH− cells. The ALDH+ cells presented CSC features such as higher levels of SOX2, NANOG and Nestin, formed more sphere-like structures and had higher resistance to 5-FU and cisplatin (Zhi et al., 2011). They also showed that ALDH+ cells were more sensitive to salinomycin, a drug proposed to target CSCs (Zhi et al., 2011).

**Colorectal Cancer**

Several specific cell-surface markers were used to identify colorectal CSCs (Todaro et al., 2016; Vaiopoulos et al., 2012; Rassouli et al., 2016; Wahab et al., 2017; Zhou et al., 2017; Boesch et al., 2018; Munro et al., 2018; Parizadeh et al., 2019; van der Heijden and Vermeulen, 2019). CD133 was shown to be a robust CSC-surface marker in CRC (O’Brien et al., 2007; Ricci-Vitiani et al., 2007; Akbari et al., 2020). Positive expression of CD133 was, for the first time, associated with a significantly worse survival and poorer clinical response to 5-FU-based chemotherapy in CRC patients (Ong et al., 2010). CD44 is also a valid marker of colorectal CSCs (Du et al., 2008). In combination with EpCAM it has already been considered a better strategy, when compared to CD133 (Dalerba et al., 2007b). Furthermore, CD166 (another transmembrane glycoprotein) could be used to co-purify CSCs (Dalerba et al., 2007b). More recently, colonospheres and chemoresistant CRC cells were found to be enriched with CD133 and CD44 (Huang et al., 2015). A strategy that combines CD133 with CD44, seems to be more reliable to isolate colorectal CSCs from both cell lines and primary tumors (Abbasian et al., 2019). Horst et al. (2009) showed that CD133 may have a better prognostic capacity per se, but the combination of CD133, CD44, and CD166 markers may stratify better the risk of CRC. Lgr5 positivity identifies human colorectal CSCs and is a prognostic factor for CRC (Kemper et al., 2012; Jiang Y. et al., 2016). Lgr5 overexpression has been shown to be important in
have shown that spheroid cultures of colon CSCs express CD133, of CSCs in CRC (Leng et al., 2018). Vermeulen et al. (2008) with CD44 and EpCAM can further improve the identification a rapid tumor growth when treatment ends. Lgr5 combined + markers as well as to uncover targetable molecular features One of the challenges to target CSCs is to identify specific POTENTIAL CSC MARKERS

One of the challenges to target CSCs is to identify specific markers as well as to uncover targetable molecular features associated with their phenotype. It is known that normal stem cells and CSCs share core stemness signaling pathways such as Notch, Hedgehog, WNT/β-catenin and JAK/STAT, that have pivotal roles in maintaining stem cell properties and regulating their transcriptional program (Chen K. et al., 2013). SOX2, OCT4, KLF4, and NANOG are some of the key TFs known to promote stemness by upregulating genes involved in self-renewal and pluripotency, while suppressing genes involved in differentiation (Young, 2011; Tang et al., 2015; Buczek et al., 2018). Key stem cell TFs like SOX2, OCT4, and NANOG have been proven to be overexpressed in CSCs. For that reason, fluorescence reporter systems driven by portions of promoters where these proteins bind were developed to allow CSCs to be labeled and tracked in various types of cancer. These reporter systems seem to be a powerful tool to identify and study CSCs more efficiently than cell-surface markers (Saygin et al., 2016). Tang et al. (2015) developed a flexible lentiviral-based reporter system (SORE6-GFP) that allows direct visualization of CSCs based on SOX2 and OCT4 expression. By using this novel reporter system, our group was able to isolate gastric CSCs from two phenotypically different GC cell lines (AGS and Kato III) (Pádua et al., 2020). Using the same principle, other authors have been developing similar systems to identify and characterize CSCs in a variety of solid tumors. Buczek et al. (2018) established a method using a lentiviral construct carrying the promoter of NANOG to identify prostate CSCs and more recently, Ghanei et al. (2020) introduced a similar approach for the isolation of CSCs in a breast cancer cell line based on the single expression of OCT4. Although the use of cell-surface markers is the most trusted approach to detect these cells, several studies demonstrated that they lack specificity and cannot be used for real time assessment of CSCs behavior, which could give new insights about their properties and possible targets (Tang et al., 2015). Growing evidences support that specific TFs overexpressed in normal gastrointestinal stem cells may contribute to the self-renewal characteristics of CSCs in GC and CRC and are related with patient prognosis (Hadjimichael et al., 2015; Zhao et al., 2017). This makes them a powerful tool in CSCs identification and study.

**SOX2 (SRY-Box Transcription Factor 2)**

SOX2 is a master regulator that belongs to the family of high-mobility group TFs. It plays many roles throughout development and cell differentiation in normal tissues, namely in mammalian embryogenesis, morphogenesis and homeostasis of the foregut-derived epithelia of the esophagus, lung and trachea (Avilion et al., 2003; Sarkar and Hochedlinger, 2013). SOX2 role in stemness was strengthened with Takahashi and Yamanaka's findings when reprogramming mouse embryonic fibroblasts into induced pluripotent stem (iPS) cells, by introducing SOX2 along with OCT3/4, c-Myc and KLF4 (Takahashi and Yamanaka, 2006). In cancer, SOX2 has increasingly been associated with a CSC phenotype in several tumors (Wuebben and Rizzino, 2017; Takeda et al., 2018). In GC, SOX2 role is still controversial: some authors associate its high expression with a more aggressive phenotype, poor prognosis and worse response to therapy whereas others have shown the opposite (Hütz et al., 2013; Camilo et al., 2014; Carrasco-Garcia et al., 2016; Zhang X. et al., 2016; Wuebben and Rizzino, 2017; Basati et al., 2020; Pádua et al., 2020). Our group identified subpopulations of gastric CSCs in two human cell lines based on the expression of SOX2 and showed that SORE6+ cells presented CSCs properties, including higher proliferation and ability to form gastrofibres, enhanced in vivo tumorigenesis and increased resistance to 5-FU (Pádua et al., 2020). Additionally, Hütz et al. (2013) observed that inhibition of SOX2 resulted in reduced cell proliferation and migration, increased apoptosis, changes in cell cycle and reduced tumorigenic potential of cells in vivo. Similar results were observed in vivo, where suppression of SOX2 resulted in reduced tumor growth and decreased tumorigenicity (Tian et al., 2012; Hütz et al., 2013). In CRC, SOX2 overexpression has been associated with tumor progression and disease recurrence and SOX2 de novo expression was associated with poorly differentiated and more invasive tumors and poor patient overall survival (Lundberg et al., 2014; Lundberg et al., 2016). Takeda et al. (2018) have shown that SOX2+ cells developed chemoresistance to oxaliplatin and 5-FU, exhibiting typical asymmetric cell division and higher CSC markers expression. They concluded that colon cancer cells expressing SOX2 behave like CSCs and are therefore associated with poor prognosis (Lundberg et al., 2016; Takeda et al., 2018). Taken together, these findings indicate that SOX2 has a critical role in several aspects of CSCs biology.

**TRANSCRIPTION FACTORS AS POTENTIAL CSC MARKERS**

One of the challenges to target CSCs is to identify specific markers as well as to uncover targetable molecular features associated with their phenotype. It is known that normal stem cells and CSCs share core stemness signaling pathways such as Notch, Hedgehog, WNT/β-catenin and JAK/STAT, that have pivotal roles in maintaining stem cell properties and regulating their transcriptional program (Chen K. et al., 2013). SOX2, OCT4, KLF4, and NANOG are some of the key TFs known to promote stemness by upregulating genes involved in self-renewal and pluripotency, while suppressing genes involved in differentiation (Young, 2011; Tang et al., 2015; Buczek et al., 2018). Key stem cell TFs like SOX2, OCT4, and NANOG have been proven to be overexpressed in CSCs. For that reason, fluorescence reporter systems driven by portions of promoters where these proteins bind were developed to allow CSCs to be labeled and tracked in various types of cancer. These reporter systems seem to be a powerful tool to identify and study CSCs more efficiently than cell-surface markers (Saygin et al., 2016). Tang et al. (2015) developed a flexible lentiviral-based reporter system (SORE6-GFP) that allows direct visualization of CSCs based on SOX2 and OCT4 expression. By using this novel reporter system, our group was able to isolate gastric CSCs from two phenotypically different GC cell lines (AGS and Kato III) (Pádua et al., 2020). Using the same principle, other authors have been developing similar systems to identify and characterize CSCs in a variety of solid tumors. Buczek et al. (2018) established a method using a lentiviral construct carrying the promoter of NANOG to identify prostate CSCs and more recently, Ghanei et al. (2020) introduced a similar approach for the isolation of CSCs in a breast cancer cell line based on the single expression of OCT4. Although the use of cell-surface markers is the most trusted approach to detect these cells, several studies demonstrated that they lack specificity and cannot be used for real time assessment of CSCs behavior, which could give new insights about their properties and possible targets (Tang et al., 2015). Growing evidences support that specific TFs overexpressed in normal gastrointestinal stem cells may contribute to the self-renewal characteristics of CSCs in GC and CRC and are related with patient prognosis (Hadjimichael et al., 2015; Zhao et al., 2017). This makes them a powerful tool in CSCs identification and study.
NANOG is associated with a CSC phenotype, it remains unclear (Ruiz et al., 2014; Basati et al., 2020). Although studies indicate expressed in GC and significantly associated with tumor size (et al., 2015). Previous studies demonstrate that NANOG is highly expressed in colon CSCs and its knockdown affects the stemness phenotype and decreases the cells malignant profile, suggesting it may act as a novel prognostic marker in CRC (Miyoshi et al., 2010, 2018; Dai et al., 2013; Amini et al., 2014).

KLF4 (Kruppel Like Factor 4)
KLF4, also known as the gut-enriched Kruppel like factor (GKLF), is strongly expressed in post-mitotic and terminally differentiated epithelial tissues, along with those of the gastrointestinal tract (Cho et al., 2007; Cui et al., 2013). It is suggested that it may have an anticancer role in GC, being downregulated due to hypermethylation and loss of heterozygosity in gastric CSCs (Cho et al., 2007). Several studies have shown that KLF4 low expression is negatively associated with patient overall survival and may be a useful prognostic marker in GC patients (Li et al., 2012; Zhang et al., 2012; Hsu et al., 2013; Hashimoto et al., 2017; Zhao et al., 2020). Regarding CRC, KLF4 role is still not clear. Some studies reveal KLF4 is overexpressed in colon CSCs and its knockdown affects the stemness phenotype and decreases the cells malignant profile, while others demonstrate that loss of expression is associated with stem-like features namely formation of colonospheres, cell growth arrest, uncontrolled cell proliferation, pluripotency and self-renewal (Shie et al., 2000; Wei et al., 2006; Leng et al., 2013; Hadjimichael et al., 2015).

NANOG (Nanog Homeobox)
NANOG was first discovered in embryonic stem cells (ESCs) and is a key TF involved in self-renewal and multipotency (Chambers et al., 2003). It is typically silenced in normal somatic cells; though abnormal expression has been reported in malignant tumors, such as GC and CRC (Lin et al., 2012; Hadjimichael et al., 2015). Previous studies demonstrate that NANOG is highly expressed in GC and significantly associated with tumor size and grade, along with decreased overall survival (Iv Santaliz-Ruiz et al., 2014; Basati et al., 2020). Although studies indicate NANOG is associated with a CSC phenotype, it remains unclear its role in CSC maintenance in GC (Iv Santaliz-Ruiz et al., 2014). With respect to CRC, NANOG overexpression has been associated with colony formation and stem cell properties, as well as worse prognosis (Ibrahim et al., 2012; Zhang et al., 2013; Hadjimichael et al., 2015).

c-Myc (MYC Proto-Oncogene, bHLH Transcription Factor)
c-Myc is an essential TF that regulates genes that take part in biological processes such as self-renewal, differentiation, growth and metabolism (Dang, 2013; Bretones et al., 2015). Although it is one of the most commonly activated oncogenes involved in the pathogenesis of cancer, its overexpression alone is unable to induce the transformation of normal cells into tumor cells (Yang et al., 2020). The role of c-Myc in GC is less studied than in other tumor types. It has been suggested as a CSC marker in some tumors such as small-cell lung cancer, prostate cancer, neuroblastoma, glioblastoma and hematopoietic malignancies, but the expression and relevance in GC has not yet been clarified (Yang et al., 2020). Some authors associate c-Myc deregulation with poor prognostic features (Han et al., 1999; de Souza et al., 2013; Wang et al., 2016). Upregulation of c-Myc is common in 70% of CRC cases and it has been shown to have a crucial role in maintaining chemoresistance and self-renewal, being overexpressed in colon CSCs (Muzny et al., 2012; Zhang et al., 2019). Despite some controversial results, it has been shown that high expression of c-Myc is an independent poor prognostic factor in CRC (Lee et al., 2015; Wang et al., 2017).

SOX9 (SRY-Box Transcription Factor 9)
SOX9 regulates developmental processes such as male sex determination, chondrogenesis, neurogenesis, and neural crest development (Jo et al., 2014). Also, it plays a vital role in cell fate decisions and stem cell maintenance during embryonic development and adulthood in several organs, including the gastrointestinal tract (Bastide et al., 2007; Huch and Clevers, 2011). Its role in GC is still conflicting, while some studies defend an association between lower survival and SOX9 high expression, others demonstrate poor prognosis with a decreased level of SOX9 expression (Sun et al., 2012; Santos et al., 2016; Mesquita et al., 2019). Also, both oncogenic and tumor suppressor activity of SOX9 have been implicated in CRC (Darido et al., 2008; Lu et al., 2008; Matheu et al., 2012; Prévostel and Blanche, 2017). Previous studies suggest that this TF can influence tumor proliferation and progression, mainly through the regulation of the CSC pool, and could correlate with poor prognosis (Lu et al., 2008; Espersen et al., 2015; Javier et al., 2016).

GLI1 (GLI Family Zinc Finger 1)
GLI1 is part of the Sonic Hedgehog (SHH) pathway and seems to be essential for the maintenance of cancer cells with stem like properties in both GC and CRC (Zhang X. et al., 2016; Yang et al., 2018). In GC, its expression is significantly higher in metastatic cancer tissues and is positively correlated with a more aggressive tumor phenotype (Zhang X. et al., 2016). Furthermore, it has been observed that GLI1 overexpression promotes a CSC phenotype enhancing cell proliferation, migration and therapy.
β-Catenin (Catenin Beta 1)

The Wnt/β-catenin pathway is implicated in the regulation of the epithelial stem cell self-renewal (Behrens et al., 1996). Alone, β-catenin signaling has been shown as necessary for the maintenance of CSC features (Huang et al., 2007; Kanwar et al., 2010; Jiang R. et al., 2016). The dysregulation of the Wnt/β-catenin signaling pathway has been implicated in colon carcinogenesis and plays a critical role in regulating the growth and maintenance of colonospheres (Kolligs et al., 2002; Kanwar et al., 2010). The activation of this pathway can lead to the conversion of intestinal stem cells into CSCs, where expression levels of β-catenin are higher (Kanwar et al., 2010). Some studies revealed that high levels of nuclear β-catenin, in CRC patients, were associated with a poor prognosis and could be used as a biomarker for late phase CRC (Chen Z. et al., 2013). Gastric CSCs self-renewal and proliferation ability, both in vitro and in vivo, are also improved by the Wnt/β-catenin signaling (Mao et al., 2014; Chiuriollo, 2015).

CSCs AND TUMOR MICROENVIRONMENT

The close interaction between CSCs and their niche is fundamental for maintaining the stemness of CSCs and tumor progression. The CSC niche, a specific tumor microenvironment, which consists of stroma, micro-vessels, hypoxic regions, cancer-associated fibroblasts (CAFs), cancer-associated mesenchymal stem cells (MSCs), tumor-associated macrophages (TAMs) and extracellular matrix, secretes soluble factors (e.g., cytokines and growth factors) that are necessary for cancer cell survival (Quante et al., 2013; Lau et al., 2017; Yang et al., 2020). Growth factors and cytokines regulate Wnt, Notch, JAK-STAT3 and other signaling pathways thereby stimulating growth, epithelial-to-mesenchymal transition (EMT), invasion, angiogenesis, metastasis and inhibiting apoptosis (Yang et al., 2020). These pathways are required for the self-renewal and maintenance of CSCs. For instance, growth factors like hepatocyte growth factor (HGF), secreted by the stromal myofibroblasts, activate the Wnt-signaling in a subset of colon cancer cells that maintain the CSC phenotype (Vermeulen et al., 2010). Another example is hypoxia, which also maintains a stem-like phenotype in CRC and GC through the increased expression of hypoxia-inducible factors (HIFs), the transcription factors HIF-1α and HIF-2α, that maintain the Wnt/β-catenin signaling pathway and activate stemness-related TFs such as OCT4 (Gidekel et al., 2003; Liu et al., 2008; Mazumdar et al., 2010; Yeung et al., 2011; Vadde et al., 2017). On the other hand, cancer cells also secrete growth factors and proteases to promote changes in their microenvironment (Ishimoto et al., 2014). One significant example of this crosstalk between cancer cells and the microenvironment is the secretion of cytokines like interleukin-6 (IL-6) by the cancer-associated mesenchymal stem cells that enhance the progression of CRC through the IL-6/JAK2/STAT3 signaling (Zhang et al., 2018a). The same is observed in GC through the secretion of interleukin-8 (Li W. et al., 2015). On the other hand, cancer cells mediate the production of inflammatory cytokines with pro-tumorigenic roles or the inhibition of cytokines involved in immune surveillance, altering the composition of the immune cells in the tumor microenvironment (Quante et al., 2013; West et al., 2015). Specifically, Rezalof et al. (2019) suggested that CSCs could alter the cytokines in the tumor microenvironment by demonstrating that the balance between suppressive regulatory T cells (Treg) and T helper cells producing IL17 (Th17) could be affected. Chaudhry et al. (2009) disclosed further that STAT3 is fundamental for the inhibition of Treg cells development and resistance (Dong et al., 2019; Yao et al., 2019). GLI1 also plays an important role in CSC characteristics related with aggressiveness and metastatic spread of CRC cells leading to decreased survival. Furthermore, GLI1 knockdown downregulates CD133/SOX9 expression and clonogenic ability of CRC cells, indicating this TF could be a potential marker for CSCs in CRC (Yang et al., 2018).

STAT3 (Signal Transducer and Activator of Transcription 3)

STAT3 plays an important role in the regulation of various physiological functions, such as inflammation, proliferation and invasion, being highly expressed in gastric and colorectal CSCs (Yu H. et al., 2009; Lin et al., 2011; Hajimoradi et al., 2016; Sonbol et al., 2019). In gastric CSCs, high expression of STAT3 has been reported to be involved in stemness properties and invasive ability (Hajimoradi et al., 2016; Jiang et al., 2017; Sonbol et al., 2019). Regarding its prognostic value several studies report STAT3 activation as a marker of unfavorable outcome (Kim D.Y. et al., 2009; Deng et al., 2010, 2013; Ji et al., 2016). In CRC, STAT3 is one of the major oncogenic proteins associated with proliferation, angiogenesis, invasion and chemo-radiotherapy resistance (Lin et al., 2005, 2011; Munro et al., 2018). Also, its inhibition prevents tumor initiation, being an attractive therapeutic target for CRC (Lin et al., 2011).

SALL4 (Spalt Like Transcription Factor 4)

As a TF, SALL4 plays essential roles in maintaining pluripotency and self-renewal of ESCs, being downregulated or silenced in differentiated cells (Zhang et al., 2006, 2015; Yang et al., 2008). SALL4 acts as an oncogene and it is associated with cancer initiation, development, and progression (Ma et al., 2006). Zhang et al. (2014) showed that the overexpression of SALL4 is associated with gastric CSC features and could be involved in the generation and maintenance of these cells. Later, Yuan et al. (2016) suggested a novel mechanism for SALL4 role in GC, showing that this TF binds to the promoter region of CD44 and activates it expression, enhancing cell proliferation, migration and invasion. Increasing evidence indicates that upregulation of SALL4 is associated with lymph node metastasis and poorer overall prognosis (Zhang et al., 2014, 2018b). In CRC, SALL4 overexpression is detected in 87% of tumor tissues and it is correlated with tumor cell metastasis to lymph nodes being associated with poor prognosis and showing its essential role in maintaining the properties of CSCs (Forghanifard et al., 2013; Zhang et al., 2015).

β-catenin/β-Catenin signaling pathway has been implicated in colon carcinogenesis and plays a critical role in regulating the growth and maintenance of colonospheres (Kolligs et al., 2002; Kanwar et al., 2010). The activation of this pathway can lead to the conversion of intestinal stem cells into CSCs, where expression levels of β-catenin are higher (Kanwar et al., 2010). Some studies revealed that high levels of nuclear β-catenin, in CRC patients, were associated with a poor prognosis and could be used as a biomarker for late phase CRC (Chen Z. et al., 2013). Gastric CSCs self-renewal and proliferation ability, both in vitro and in vivo, are also improved by the Wnt/β-catenin signaling (Mao et al., 2014; Chiuriollo, 2015).
Th17 differentiation. In fact, the STAT3 transcription factor, in collaboration with NFκB, regulates the expression of these genes encoding critical cancer-promoting inflammatory mediators, establishing a crosstalk between cancer and immune cells of the microenvironment and perpetuating the effects of STAT3 activation in cancer cells (Yu et al., 2007; Grivennikov and Karin, 2010; Yang et al., 2019). However, despite the growing evidences on the interaction of gastric and colorectal CSCs with the tumor microenvironment, the specific molecules involved and their signaling pathways still need further investigation in order to design safe therapies.

**THERAPEUTIC APPROACHES TO TARGET CSCs**

The therapeutic approach in GC and CRC is determined by the stage of the disease at the time of diagnosis. Patients are treated with surgery, chemotherapy and/or radiation. In GC, surgery remains the main treatment for stage I. It can also be performed at stages II and III but chemotherapy (perioperative, neoadjuvant or adjuvant) is necessary to improve overall survival of the patients. For stage IV, chemotherapy with doublet or triplet platinum/fluoro-pyrimidine combinations or capecitabine is the main treatment (Neri et al., 2007; Smyth et al., 2016). Resective surgery is the main curative treatment used in non-metastasized CRC, although neo-adjuvant treatments are also administered in rectal carcinoma (Kuipers et al., 2015). After surgery, 5-FU-based chemotherapy is used to reduce the risk of tumor recurrence and improve overall survival of patients (Dienstmann et al., 2017). Currently, the decision of giving adjuvant treatment to early-stage CRC patients is recommended to high risk patients with one or more risk factors (Kannarkatt et al., 2017). Patients with very high risk – microsatellite stable (MSS) and T4 may be considered for the addition of oxaliplatin (Labianca et al., 2013). However, in some cases of GC and CRC, after a believed efficacious treatment, the cancer reappears locally or in distant metastasis. This results from the presence of CSCs that were able to resist the therapy applied, revealing that the existence of CSCs is one of the biggest difficulties in cancer treatment (Dean et al., 2005). Thus, direct targeting of CSCs seems to be the key for tumor complete elimination. The therapy against CSCs using specific molecules should eradicate these cells while the conventional therapy eliminates the non-CSCs present in the tumor bulk. Nevertheless, this type of treatment should be administrated in combination due to the possibility of cell plasticity that facilitates the appearance of de novo CSCs from non-CSCs. Moreover, targeting specific TFs or signaling pathways responsible for maintaining the CSC phenotype could become novel therapies against GC and CRC. For that reason, several clinical trials are being undertaken to explore the efficacy of diverse compounds, that are capable of modulating or inactivating proteins that gastric and colorectal CSCs use to grow and survive, allowing their elimination. Additionally, it is worth to mention that several studies have been conducted to evaluate the efficacy of small molecules in targeting CSCs in vitro and in vivo, compounds capable of eliminating or reducing the CSC population that could also be part of the path in cancer therapy targeting CSCs (Gupta et al., 2009; Abetov et al., 2015; Shapiro et al., 2016; Müller et al., 2017; Park et al., 2017; Pádua et al., 2020). Table 2 lists the drugs that have been or are being investigated in clinical trials, alone or in combination with other compounds, to treat GC and CRC.

**Immunotherapy**

Cancer immunotherapy has emerged as a potential tool for cancer treatment (Farkona et al., 2016). Several immunotherapeutic strategies have been developed including cancer vaccines, oncolytic viruses, monoclonal antibodies or recombinant proteins, chimeric antigen receptor T cell (CAR-T) cells and other cellular therapies, lymphocyte-activating cytokines and checkpoint inhibitors (Riley et al., 2019). Immunotherapy aims to improve the immune system response against cancer cells through natural mechanisms (Riley et al., 2019). Therefore, it can be used to target cancer cells and also CSCs in the tumor microenvironment (Badrinath and Yoo, 2019). Many immunotherapeutic agents targeting CSCs have been tested in clinical trials (Menon et al., 2016). Monoclonal antibodies that specifically target CSC surface biomarkers have been used in gastric and colorectal cancer. Ongoing there is a Phase I study of RO5429083, a monoclonal antibody against CD44 in patients with metastatic and/or locally advanced malignant solid tumors (NCT01358903). Also used were EpCAM antibodies, such as edrecolomab, that was tested in patients with resected stage II adenocarcinoma of the colon (Niedzwiecki et al., 2011) and adecatumumab, that is being tested in a Phase II study to evaluate efficacy and safety, alone or with FOLFOX, in metastasized CRC (NCT00866944). A Phase I dose finding study is evaluating the bispecific antibody targeting EGFR and Lgr5 (MCLA-158) in metastatic CRC and other advanced solid tumors (NCT03526835). In addition, CAR-T cell therapies, have been developed to target CSCs in GC and CRC. There are three Phase I or II clinical trials in GC using CAR-T cells targeting EpCAM (NCT03013712, NCT03563326, and NCT02725125), one of them consisting in the intraperitoneal infusion in advanced GC with peritoneal metastasis. NCT03013712 includes patients with colon cancer. Moreover, there is a Phase I/II clinical study of CAR-T cells targeting CD133 in relapsed and/or chemotherapy refractory malignancies including CRC (NCT02541370).

**Targeting the Transcription Factor STAT3**

From the list of TFs strongly associated with CSC phenotype in GC and CRC, STAT3 became crucial as a molecular target for cancer therapy because napabucasin (BBI608), the first-in-class cancer stemness (CSCs) inhibitor that works by targeting STAT3, effectively blocks cancer relapse and metastasis in xenografted human cancers (Li Y et al., 2009; Abetov et al., 2015; Shapiro et al., 2016; Müller et al., 2017; Park et al., 2017; Pádua et al., 2020). Table 2 lists the drugs that have been or are being investigated in clinical trials, alone or in combination with other compounds, to treat GC and CRC.
### Complete and ongoing clinical trials of therapeutic agents targeting gastric and/or colorectal CSCs, correlated signaling pathways and the transcription factor STAT3.

| Drug/Antibody         | Targets | Disease/Condition                              | NCT Identifier   | Phase | Routes of administration | Recruitment status                      | Last update       | Sponsor                                           |
|-----------------------|---------|-----------------------------------------------|------------------|-------|--------------------------|-----------------------------------------|-------------------|---------------------------------------------------|
| **Immunotherapy**     |         |                                               |                  |       |                          |                                         |                   |                                                   |
| RO5429083             | CD44    | Metastatic and/or locally advanced malignant solid tumors | NCT01368903      | I     | Intravenous (IV)         | Completed, no results posted            | November 2016     | Hoffmann-La Roche                                 |
| Adecatumumab alone or in combination with FOLFOX | EpCAM | Resection of colorectal liver metastases | NCT00866944      | II    | Intravenous (IV)         | Completed, no results posted            | November 2011     | Amgen Research (Munich) GmbH                       |
| MCLA-158              | EGFR and Lgr5 | Advanced/metastatic solid tumors, including CRC | NCT03528835      | I     | Intravenous (IV)         | Recruiting                              | August 2018       | Merus N.V.                                        |
| EpCAM CAR-T           | EpCAM   | Relapsed or refractory EpCAM positive cancer | NCT03013712      | I/II  | Intravenous (IV)         | Recruiting                              | January 2017      | First Affiliated Hospital of Chengdu Medical College |
| EpCAM CAR-T           | EpCAM   | Advanced GC with peritoneal metastasis       | NCT03663326      | I     | Intravenous (IV)         | Recruiting                              | September 2018    | Jian-Kun Hu                                       |
| EpCAM CAR-T           | EpCAM   | GC                                            | NCT02725125      | —     | Intravenous (IV)         | Unknown                                 | March 2017        | Sinobioway Cell Therapy Co., Ltd.                  |
| CART-133              | CD133   | Chemotherapy refractory advanced malignancies, including CRC | NCT02541370      | I/II  | Intravenous (IV)         | Completed, no results posted            | December 2019     | Chinese PLA General Hospital                       |
| **Transcription Factor inhibitors** |         |                                               |                  |       |                          |                                         |                   |                                                   |
| BBI608 or BNC105 in combination with nivolumab | STAT3   | Metastatic CRC                               | NCT03647939      | II    | Oral and Intravenous (IV) | Recruiting                              | February 2019     | Australasian Gastro-Intestinal Trials Group       |
| Danvatirsen (AZD9150) in combination with Durvalumab (MEDI4738) | STAT3   | Advanced and refractory pancreatic, non-small cell lung cancer, and mismatch repair deficient CRC | NCT02983578      | II    | Intravenous (IV)         | Recruiting                              | March 2020        | M.D. Anderson Cancer Center                        |
| Napabucasin (GB201) in combination with FOLIRI | STAT3   | Metastatic CRC                               | NCT03522649      | III   | Oral and Intravenous (IV) | Recruiting                              | June 2019         | 1Globe Health Institute LLC                        |
| TTI-101               | STAT3   | Advanced cancers, including gastric adenocarcinoma and CRC | NCT03195699      | I     | Oral                     | Recruiting                              | February 2020     | Tvardi Therapeutics, Incorporated                  |

(Continued)
| Drug                                | Targets                        | Disease/Condition                        | NCT Identifier       | Phase | Routes of administration | Recruitment status | Last update  | Sponsor                                                                 |
|------------------------------------|--------------------------------|------------------------------------------|----------------------|-------|--------------------------|-------------------|--------------|--------------------------------------------------------------------------|
| Artesunate, prior to surgery       | β-catenin                      | Stage II/III CRC                        | NCT0233098           | II    | Oral                     | Recruiting        | April 2019    | St George's, University of London                                        |
| DKN-01 in combination with atezolizumab | DKK1                           | GC                                       | NCT04166721          | I/I   | Intravenous (IV)         | Recruiting        | February 2020   | Royal Marsden NHS Foundation Trust                                      |
| ETC-1922159 in combination with pembrolizumab | PORCN                         | Advanced solid tumors                   | NCT02521844          | I     | Oral and Intravenous (IV)| Active, not recruiting | October 2019  | EDDC (Experimental Drug Development Centre), A*STAR Research Entities |
| Foxy-5                             | Wnt-5A                         | CRC                                      | NCT0200291           | I     | Intravenous (IV)         | Completed, no results posted | February 2016  | WntResearch AB                                                           |
| Foxy-5                             | Wnt-5A                         | Metastatic breast, colon or prostate cancer | NCT02655962          | I     | Intravenous (IV)         | Completed, no results posted | December 2018  | WntResearch AB                                                           |
| Foxy-5 as neo-adjuvant therapy     | Wnt-5A                         | Colon cancer                             | NCT03883802          | II    | Intravenous (IV)         | Recruiting        | April 2019     | WntResearch AB                                                           |
| Genistein in combination with FOLFOX or FOLFOX-Avastin | tyrosine kinase and topoisomerase-II | Metastatic CRC                          | NCT01985763          | I/I   | Oral and Intravenous (IV)| Completed, has results | May 2019       | Sofya Pintova                                                         |
| LGK974                             | PORCN                          | Malignancies dependent on Wnt ligands, including BRAF mutant CRC | NCT01351103          | I     | Oral                     | Recruiting        | February 2020  | Novartis Pharmaceuticals                                                  |
| LGK974 in combination with LGX818 and cetuximab | PORCN                         | BRAF-mutant metastatic CRC and Wnt pathway mutations metastatic CRC | NCT02278133          | I/I   | Oral                     | Completed, no results posted | October 2017   | Array BioPharma                                                        |
| MCLA-158                           | EGFR and LGR5                  | Advanced/metastatic solid tumors, including CRC | NCT03526835          | I     | Intravenous (IV)         | Recruiting        | August 2018    | Merus N.V.                                                               |
| Mesalazine                         | induces the expression of µ-protocadherin | CRC                                    | NCT02077777          | II    | Oral                     | Completed, no results posted | December 2016  | SOFAR S.p.A.                                                           |
| OMP-18R5 (Vantictumab)             | Wnt receptor                   | Solid tumors                            | NCT01608867          | I     | Intravenous (IV)         | Completed, no results posted | September 2016  | OncoMed Pharmaceuticals, Inc.                                            |
| OMP-54F28 (Ipafricept)             | Wnt receptor                   | Solid tumors                            | NCT01608867          | I     | Intravenous (IV)         | Completed, no results posted | July 2017      | OncoMed Pharmaceuticals, Inc.                                            |

(Continued)
### TABLE 2 | Continued

| Drug | Targets | Disease/Condition | NCT Identifier | Phase | Routes of administration | Recruitment status | Last update | Sponsor |
|------|---------|-------------------|----------------|-------|--------------------------|------------------|-------------|---------|
| **Hedgehog (Hh) pathway inhibitors** | | | | | | | |
| BMS-833923 (KL139) | Smoothened | Advanced or metastatic solid tumors | NCT01413906 | I | Oral | Completed, no results posted | June 2013 | Bristol-Myers Squibb |
| BMS-833923 in combination with cisplatin and capecitabine | Smoothened | Metastatic gastric, gastroesophageal, or esophageal adenocarcinomas | NCT00909402 | I | Oral and Intravenous (IV) | Completed, no results posted | June 2013 | Bristol-Myers Squibb |
| LDE255 (Sonidegib) in combination with BKM120 (Buparlisib) | Smoothened (and PI3K) | Advanced solid tumors | NCT01576666 | I | Oral | Completed, no results posted | February 2016 | Novartis Pharmaceuticals |
| LEQ-506 | Smoothened | Advanced solid tumors | NCT01106508 | I | Oral | Completed, no results posted | February 2020 | Novartis Pharmaceuticals |
| Vismodegib in combination with standard chemotherapy | Smoothened | Advanced GC or gastroesophageal junction cancer | NCT00982592 | II | Oral and Intravenous (IV) | Completed, has results | January 2016 | National Cancer Institute (NCI) |
| Vismodegib (GDC-0449) with concurrent chemotherapy and bevacizumab as first-line therapy | Smoothened | Metastatic CRC | NCT00636610 | II | Oral | Completed, has results | June 2017 | Genentech, Inc. |

| **NOTCH pathway inhibitors** | | | | | | | |
| BMS-906024 | Pan-Notch | Advanced or metastatic solid tumors | NCT01292655 | I | Intravenous (IV) | Completed, no results posted | January 2020 | Bristol-Myers Squibb |
| CB-103 | Pan-Notch | Advanced or metastatic solid tumors, including CRC | NCT03422679 | I/II | Oral | Recruiting | May 2019 | Cellestia Biotech AG |
| LY3039478 (Crenigacestat) | Pan-Notch | Advanced solid tumors | NCT02836600 | I | Oral | Active, not recruiting | December 2019 | Eli Lilly and Company |
| LY3039478 (Crenigacestat) in combination with other anticancer agents | Pan-Notch | Advanced or metastatic solid tumors | NCT02784795 | I | Oral and Intravenous (IV) | Completed, no results posted | March 2020 | Eli Lilly and Company |
| LY900009 | γ-Secretase | Advanced cancer | NCT01158404 | I | Oral | Completed, has results | August 2019 | Eli Lilly and Company |
| MEDI0639 | DLL4 | Advanced solid tumors | NCT01577745 | I | Intravenous (IV) | Completed, has results | May 2017 | MedImmune LLC |
| REGN421 (SAR153192; Enoticumab) | DLL4 | Advanced solid malignancies | NCT00871559 | I | Intravenous (IV) | Completed, no results posted | March 2014 | Regeneron Pharmaceuticals |

(Continued)
### TABLE 2 | Continued

| Drug | Targets | Disease/Condition | NCT Identifier | Phase | Routes of administration | Recruitment status | Last update | Sponsor |
|------|---------|-------------------|----------------|-------|--------------------------|--------------------|-------------|---------|
| RO4929097 | γ-Secretase | Recurrent and metastatic CRC | NCT01116887 | II | Oral | Completed, has results | May 2014 | National Cancer Institute (NCI) |
| RO4929097 | γ-Secretase | Refractory solid tumors | NCT01158274 | I | Oral | Completed, no results posted | November 2014 | National Cancer Institute (NCI) |
| RO4929097 | γ-Secretase | Advanced solid tumors including CRC | NCT01131234 | I | Oral | Completed, no results posted | December 2014 | National Cancer Institute (NCI) |

**PI3K/AKT/mTOR pathway inhibitors**

| Drug | Targets | Disease/Condition | NCT Identifier | Phase | Routes of administration | Recruitment status | Last update | Sponsor |
|------|---------|-------------------|----------------|-------|--------------------------|--------------------|-------------|---------|
| Acetylsalicylic acid (aspirin) | | CRC stage I-III with mutations in the PI3K signaling pathway | NCT02647099 | III | Oral | Recruiting | August 2019 | Anna Martling |
| Acetylsalicylic acid (aspirin) | | Resected colon cancer with PI3K mutation stage II or III high risk | NCT02945033 | III | Oral | Recruiting | October 2019 | University Hospital, Rouen |
| Acetylsalicylic acid (aspirin) | | Dukes C and high-risk dukes B CRCs | NCT00565708 | III | Oral | Recruiting | September 2019 | National Cancer Centre, Singapore |
| Acetylsalicylic acid (aspirin) and metformin | | Stage I-III CRC patients | NCT03047837 | III | Oral | Recruiting | February 2019 | Ente Ospedaliero Ospedali Galliera |
| AZD2014 (Vistusertib) | mTORC1 and mTORC2 | RICTOR amplified GC | NCT03061708 | II | Oral | Terminated (lack of efficacy) | May 2019 | Samsung Medical Center |
| AZD2014 (Vistusertib) | mTORC1 and mTORC2 | TSC1/2 mutated or TSC1/2 null GC | NCT03082833 | II | Oral | Terminated (lack of efficacy) | May 2019 | Samsung Medical Center |
| AZDS363 in combination with paclitaxel | AKT | Advanced gastric adenocarcinoma | NCT02451956 | II | Oral and Intravenous (IV) | Completed, no results posted | December 2019 | Samsung Medical Center |
| AZD8186 in combination with paclitaxel | PI3K β/δ | Advanced GC | NCT04001569 | I/II | Oral and Intravenous (IV) | Recruiting | June 2019 | Seoul National University Bundang Hospital |
| BKM120 (Buparlisib) in combination with LDE255 (Sonidegib) | PI3K and Smoothened | Advanced solid tumors | NCT01576666 | I | Oral | Completed, no results posted | February 2016 | Novartis Pharmaceuticals |
| BYL719 (Alpelisib) in combination with AU922 | PI3K | Advanced or metastatic GC | NCT01613950 | I | Oral and Intravenous (IV) | Completed, no results posted | February 2020 | Novartis Pharmaceuticals |
| BYL719 (Alpelisib) in combination with LGX818 (Encorafenib) and Cetuximab | BRAF, EGFR and PI3K | in BRAF Mutant Metastatic CRC | NCT01719380 | I/II | Oral and Intravenous (IV) | Completed, no results posted | April 2019 | Array BioPharma |
| Drug | Targets | Disease/Condition | NCT Identifier | Phase | Routes of administration | Recruitment status | Last update | Sponsor |
|------|---------|------------------|----------------|-------|--------------------------|-------------------|-------------|---------|
| Cabozantinib | Multikinases | Refractory metastatic CRC | NCT03542877 | II | Oral | Active, not recruiting | April 2019 | Academic Thoracic Oncology Medical Investigators Consortium |
| **CB-839** (Telaglenastat) in combination with capcitabine | Glutaminase | Solid tumors and fluoropyrimidine resistant PIK3CA mutant CRC | NCT02861300 | I/II | Oral | Recruiting | March 2020 | Case Comprehensive Cancer Center |
| Copanlisib in combination with anti-PD-1 antibody Nivolumab | PI3K | Relapsed/refractory solid tumors, mismatch-repair proficient (MSS) CRC | NCT03711056 | I/II | Intravenous (IV) | Recruiting | July 2019 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins |
| DS-7423 | PI3K and mTOR | Advanced solid malignant tumors | NCT01364844 | I | Oral | Completed, no results posted | February 2014 | Daiichi Sankyo, Inc. |
| Ipatasertib (GDC-0068) in combination with oxaliplatin, 5-FU and leucovorin | AKT | Advanced or metastatic GC or gastroesophageal junction cancer | NCT01896531 | I/II | Oral and Intravenous (IV) | Active, not recruiting | February 2020 | Genentech, Inc. |
| **MK-2206** | AKT | Advanced GC or gastroesophageal junction cancer | NCT01260701 | II | Oral | Completed, has results | January 2016 | National Cancer Institute (NCI) |
| **MK-2206** | AKT | CRC that is metastatic or locally advanced and cannot be removed by surgery | NCT01802320 | II | Oral | Completed, has results | September 2019 | National Cancer Institute (NCI) |
| **MK-2206** in combination with AZD6244 (Selumetinib) | AKT and MEK | Advanced CRC | NCT01333475 | II | Oral | Completed, has results | September 2015 | National Cancer Institute (NCI) |
| Neratinib in combination with Trastuzumab or with Cetuximab | HER2 and EGFR | KRAS/NRAS/BRAF/PIK3CA wild-type metastatic CRC by HER2 status | NCT03457896 | II | Oral | Recruiting | November 2019 | NSABP Foundation Inc |
| Pembrolizumab (MK-3475) combined with INCBO05465 or with Icatinib (INCB039110) | JAK1 and PI3K-delta | Advanced solid tumors, including CRC | NCT02646748 | I | Oral | Active, not recruiting | December 2019 | Incyte Corporation |

(Continued)
| Drug | Targets | Disease/Condition | NCT Identifier | Phase | Routes of administration | Recruitment status | Last update | Sponsor |
|------|---------|------------------|----------------|-------|--------------------------|-------------------|-------------|---------|
| PX-866 (Sonolisib) in combination with Cetuximab | PIP3 | Incurable metastatic CRC | NCT01252628 | I/II | Oral | Completed | May 2018 | Cascadian Therapeutics Inc. |
| RAD001 (Everolimus) | TOR serine-threonine kinases | Previously treated unresectable or metastatic esophageal cancer or GC | NCT00858192 | II | Oral | Completed, has results | February 2020 | Translational Oncology Research International |
| RAD001 (Everolimus) | TOR serine-threonine kinases | Advanced GC | NCT00519324 | II | Oral | Completed, no results posted | November 2015 | Novartis Pharmaceuticals |
| RAD001 (Everolimus) in combination with AV-951(Tivozanib) | TOR serine-threonine kinases and VEGFRs 1, 2, and 3 | Gastrointestinal cancer | NCT01058655 | I/II | Oral | Completed, has results | April 2017 | Dana-Farber Cancer Institute |
| RAD001 (Everolimus) in combination with Capecitabine and Oxaliplatin | TOR serine-threonine kinases | Advanced GC | NCT01048620 | I | Oral and Intravenous (IV) | Completed, no results posted | January 2020 | Asan Medical Center |
| RAD001 (Everolimus) in combination with cisplatin and HDFL (high-dose 5-FU and leucovorin) | TOR serine-threonine kinases | Advanced GC | NCT00632268 | II | Oral and Intravenous (IV) | Completed, no results posted | August 2013 | National Taiwan University Hospital |
| SAR245409 (Voxtalisib) in combination with MSC1936369B (pimasertib) | PI3K, MTOR, MEK1 and 2 | Advanced or metastatic solid tumors (GC not included) | NCT01390818 | I | Oral | Completed, has results | March 2017 | EMD Serono |
| Serabelisib in combination with Canagliflozin | PI3Ka and SGLT2 | Advanced solid tumors | NCT04073680 | I/II | Oral | Not yet recruiting | February 2020 | Petra Pharma |
| SF1126 | PI3K | Solid tumors | NCT00907205 | I | Intravenous (IV) | Completed, no results posted | June 2013 | Semafore Pharmaceuticals |
| Trametinib in combination with Trifluridine and Tipiracil Hydrochloride | MEK | Chemotherapy-resistant RAS-mutated (PIK3CA/PTEN-Wild-Type) metastatic CRC | NCT03317119 | I | Oral | Recruiting | January 2020 | City of Hope Medical Center |

GC corresponds to gastric cancer and CRC to colorectal cancer. FOLFOX corresponds to a chemotherapy regimen with folinic acid (leucovorin), fluorouracil (5-FU) and oxaliplatin (Eloxatin) and FOLFIRI corresponds to a chemotherapy regimen with folinic acid (leucovorin), fluorouracil (5-FU) and irinotecan (Camptosar).
study – CanStem303C – a randomized phase III clinical trial done in adult patients with previously treated metastatic CRC evaluated napabucasin in combination with FOLFIRI (Grothey et al., 2017). Napabucasin monotherapy has been reported in a published phase III trial. The CO.23 trial evaluated the efficacy of napabucasin monotherapy versus placebo in metastasized CRC, which failed to demonstrate a significant difference in the napabucasin group survival. However, in a pre-specified biomarker analysis, phosphorylated STAT3 (pSTAT3)-positive patients experienced a significant survival benefit from napabucasin over placebo (Jonker et al., 2018; Sonbol et al., 2019). Another ongoing trial involving STAT3 inhibition is the phase II trial MODULATE (NCT03647839) which specifically aims to study the modulation of the tumor microenvironment using either vascular disrupting agents (BCN105) or STAT3 inhibition (BBI608), in synergy with an immune checkpoint protein (PD1) inhibitor (nivolumab). This trial is recruiting microsatellite stable, refractory CRC cases.

Targeting the Wnt/β-Catenin Signaling Pathway

Wnt/β-catenin signaling pathway is a major regulator of normal intestinal development and its over-activation behaves as a hallmark of CRC, being particularly significant in drug resistance and stemness maintenance of colorectal CSCs (Takebe et al., 2011; Basu et al., 2016). The activation of the Wnt/β-catenin signaling pathway is associated with poor prognosis (Janssen et al., 2006). It results mostly from the accumulation of mutations in the APC tumor suppressor gene, oncogenic KRAS-signaling pathway, β-catenin and p53. Mutations that do not allow the formation of the APC/Axin/GSK3β destruction complex result in the accumulation and nuclear translocation of β-catenin that binds to transcription factors of T cell factor family (TCF4) and activates target genes like c-Myc, cyclinD1 and survivin, some involved in maintaining stemness (Myant et al., 2013; Lee et al., 2015; Zhou et al., 2017). It has been shown that loss of APC in CRC triggered the expression of a Rac1 GTPase via the induced expression of c-Myc, necessary to intestinal stem cell proliferation and CRC initiation (Myant et al., 2013). On the other hand, p53 may affect the outcome of Wnt signaling in CRC development (Voorneveld et al., 2015), having a role in the acquisition of pluripotency during reprogramming (Takahashi and Yamanaka, 2006; Krizhanovsky and Lowe, 2009). The Wnt signaling pathway is also dysregulated in GC (Chiuirillo, 2015). However, the involvement and mechanisms are not yet as fully understood as in CRC. A number of studies suggest β-catenin and APC as driver genes, revealing somatic mutations in both genes that might have relevance in GC (Horii et al., 1992; Nakatsuru et al., 1993; Woo et al., 2001; Clements et al., 2002; Zhang and Xue, 2008). Genomic analysis of several gastric primary tumors disclosed that Wnt/β-catenin, together with NF-kB and proliferation/stem cell pathways, were deregulated in more than 70% of the primary tumors. Patient stratification by combinations of these oncogenic pathways revealed to be a great tool for GC clinical behavior assessment (Ooi et al., 2009). Many molecules have been used to target the Wnt/β-catenin in gastrointestinal CSCs (Chiuirillo, 2015; Parizadeh et al., 2019; Patel et al., 2019; Yang et al., 2020). Genistein, a soy-derived compound, was tested in a Phase I/II research trial, in combination with FOLFOX or FOLFOX-Bevacizumab, where it was demonstrated to be well tolerated by patients and may have improved efficacy in the treatment of metastatic CRC (Pintova et al., 2019). In vitro and in vivo studies have shown that Genistein affects mainly Wnt/β-catenin and PI3K/AKT pathways (Su et al., 2003; Kim et al., 2005; Zhang and Chen, 2011; Wang et al., 2012).

Targeting the Hedgehog Signaling Pathway

The dysregulation of Hedgehog (Hh) signaling pathway has been reported as another main cause of CSCs self-renewal and chemoresistance, being associated with poor clinical outcome in patients with GC or CRC (Ma et al., 2005; Varnat et al., 2009; Takebe et al., 2011; Usui et al., 2018). In this pathway, target gene expression is predominantly regulated by the Smoothened (SMO) protein but GLI inhibitors are also used (Rimkus et al., 2016; Didiasova et al., 2018). In GC cells, SMO regulates nuclear translocation of GLI-1 that in turn promotes transcription of target genes, such as CD44 (Yoon et al., 2014). Yoon et al. (2014) showed that in AGS, MKN-45, and NCI-N87 GC cell lines, the Hh pathway inhibition using SMO shRNA or small-molecule inhibitors significantly decreased spheroid formation ability and tumor growth. Vismodegib (GDC-0449), the first Hh pathway inhibitor used in cancer research, is currently undergoing Phase II trials in advanced GC and in metastatic CRC (Gupta et al., 2010; Berlin et al., 2013). Examination of tumor samples revealed that Vismodegib has not increased progression-free or overall survival as a whole, but only in a limited subset of patients with high CD44 expression (Cohen et al., 2013; Yoon et al., 2014). Disappointingly, these treatments with Vismodegib, did not increase progression-free survival in CRC patients (Low and de Sauvage, 2010; McMillan and Matsui, 2012). When the SMO inhibitor AY9944 was used in combination with the GLI-1 inhibitor GANT61, there was an increased response to anti-cancer drugs in tumor organoids and a decreased capacity to form colonies in SW480 and HCT116 CRC cells (Usui et al., 2018). These results indicate that this strategy might be worthwhile in CRC.

Targeting the Notch Signaling Pathway

The Notch signaling pathway is one of the most activated signaling pathways in cancer, namely in GC and CRC, and promotes metastatization (Du et al., 2014; Hayakawa et al., 2019). It has a key role in the maintenance and differentiation of CSCs (Quail et al., 2012; Lu et al., 2013; Yang et al., 2020). In GC and CRC, the expression of Notch1 or Jagged1 is associated with poor prognosis (Yeh et al., 2009; Kang et al., 2012; Jackstadt et al., 2018; Kim et al., 2019; Mohamed et al., 2019). In CRC, Notch1 is associated with more aggressive subtypes, recruiting neutrophils to drive metastasis (Jackstadt et al., 2019). Due to the fact that the Notch pathway is related to CSC self-renewal and angiogenesis, targeting this pathway became a potential anti-CSC therapeutic approach (Venkatesh et al., 2018). Strategies
used to inhibit Notch signaling include γ-secretase inhibition (GSI), Notch receptor (e.g., Notch1, Notch2, and Notch3) or ligand (e.g., Jagged1 and Jagged2) antibodies and combination therapy with inhibitors of other pathways. The inhibition of Notch receptors using two GSIs has allowed to disclose the importance of Notch pathway in the growth and survival of GC cells (Brzozowa et al., 2013). Furthermore, GSIs lead to the induction of apoptosis and inhibition of tumor-sphere formation of CD44+ gastric CSCs (Barat et al., 2017). However, it is important to mention that GSIs do not only target Notch-related proteins but also proteases involved in numerous cellular processes, which could originate adverse effects in vivo (Shih le and Wang, 2007; Wang et al., 2010; Brzozowa et al., 2013). Nevertheless, various clinical trials have been performed to evaluate the efficacy of targeting the Notch signaling pathway in GC and CRC (Table 2). RO4929097, a selective GSI, showed good anti-tumor activity in preclinical and early trials but it was not good enough for metastatic CRC (Luistro et al., 2009; Strosberg et al., 2012; Tolcher et al., 2012). Combinations of RO4929097 with other drugs in advanced solid tumors, including CRC, were well tolerated and presented some clinical benefit (Sahebjam et al., 2013; LoConte et al., 2015). LY900090 is another GSI tested in advanced cancers, including those of gastrointestinal tract. It is currently in a phase I trial and revealed a safety profile, with the majority of patients experiencing low-grade gastrointestinal adverse effects (Pant et al., 2016). Furthermore, it was demonstrated to have an inhibitory effect on Notch signaling pathway, inducing goblet cell differentiation and increased mucin production, similarly to that observed in rats (Pant et al., 2016). Moreover, MED160639 is a monoclonal antibody that specifically binds to DLL4 and prevents its interaction with Notch receptors, thereby inhibiting Notch-mediated signaling and target gene transcription, which may block tumor angiogenesis and eventually tumor cell growth (Ishigami et al., 2013). A phase I study in advanced solid tumors demonstrated that MED160639 is well tolerated and preliminary results show evidence of antitumor activity (Falchook et al., 2015).

**Targeting the PI3K/AKT/mTOR Signaling Pathway**

The PI3K/AKT/mTOR pathway is typically abnormally activated in many carcinomas (Michl and Downward, 2005; Johnson et al., 2010; Narayananukutty, 2019). It is thought to be crucial in angiogenesis, cell proliferation, metabolism, survival, metastasis and drug resistance (Cantley, 2002; Edinger and Thompson, 2002; Fingar et al., 2004; Al-Batran et al., 2012; Tapia et al., 2014). AKT is commonly overexpressed in tumors and plays an important role in the metabolic reprogramming of cancer (Yap et al., 2011; Iida et al., 2013). Although the PI3K/AKT/mTOR pathway has been extensively studied, there are few studies in CSCs. In GC and CRC, activation of mTOR appears to cause tumor progression and poor patient survival (Lang et al., 2007; Murayama et al., 2009; Xiao et al., 2009; Yu G. et al., 2009; An et al., 2010). Thus, its inhibition seems to be fundamental for GC and CRC therapy. A phase II study using RAD001 (everolimus) in previously treated unresectable or metastatic esophageal cancer or GC was performed over the rational that everolimus may stop tumor growth by blocking some of the fundamental enzymes for cell growth and by blocking angiogenesis. Everolimus was well tolerated by the patients however this study displayed a strong weakness by being single-arm and non-comparative. However, mTOR suppression decreased ALDH1 activity, which is a marker of CSCs in CRC (Xia and Xu, 2015). Growth inhibition, using a dual PI3K/mTOR inhibitor, PF-04691502, was observed in vitro and in xenografted CRC tumors (Fang et al., 2013). Another mTOR inhibitor decreased survival and invasion of colorectal CSCs in vitro, and suppressed tumor growth in vivo (Francipane and Lagasse, 2013). The allosteric AKT inhibitor (MK-2206) led to a decrease in CSCs proliferation, and reduction of the capacity to form colonospheres in vitro and to initiate tumor formation in vivo. Mice with xenografted tumors showed a significant decrease in tumor progression. Also, MK-2206 significantly inhibited the growth of patient-derived tumorspheres (Malkomes et al., 2016). A phase II study in advanced gastric or gastroesophageal junction cancer has revealed that MK-2206, as second-line therapy, at a dose of 60 mg was well tolerated by patients and showed some modest evidence of activity, however, the overall survival (5.1 months) was lower than the study efficacy endpoint (6.5 months) (Ramanathan et al., 2015). However, there is a Phase II clinical trial with MK-2206, to study patients with previously treated colon or rectal cancer that has spread and cannot be removed by surgery, concluding that in contrast to robust preclinical data, it does not have effect in these tumors (Dasari et al., 2016). MK-2206 was also used in combination with AZD6244 (Selumetinib), a mitogen-activated protein extracellular signal-regulated kinase (MEK)1/2 inhibitor, in a Phase II trial but the level of target inhibition obtained with the maximum non-toxic dose was not the expected (Do et al., 2015). SAR245409 (Voxitalisib) was tested in a Phase I research trial in combination with another MEK inhibitor, MSC1936369B (Pimasertib), in advanced or metastatic solid tumors (Schram et al., 2018). The primary purpose of the study was to determine the maximum tolerated dose of the drug combination. The drug RAD001 (Everolimus) downregulates mTOR. A combination of RAD001, mFOLFOX-6 and Bevacizumab has been shown to be efficacious and safe in metastatic CRC (Weldon Gilcrease et al., 2019). A multicenter phase II study for patients with refractory, metastatic CRC concluded good tolerability and efficacy of Everolimus combined with Tivozanib (an oral VEGF receptor-1, -2, -3 inhibitor) with 50% of the patients having stable disease at 2 months (Wolpin et al., 2013).

**DISCUSSION**

The identification of CSCs remains a challenging task, particularly in solid tumors like GC and CRC. The use of cell surface markers as a primary tool to identify gastric and colorectal CSCs has disclosed some weaknesses and for that reason the uncovering of more reliable biomarkers must become a priority.
These biomarkers should include the TFs that are required for the maintenance of gastric and colorectal CSCs phenotype, as well as components of the signaling pathways that have key roles in CSC features. This explains why TFs such as STAT3 and signaling pathways like Wnt/β-catenin, Hedgehog, NOTCH and PI3K/AKT/mTOR emerged as powerful targets, whose inactivation or modulation could eliminate gastric and colorectal CSCs. This fact is corroborated by several completed and ongoing clinical trials targeting these potential biomarkers in both tumor types, where some of the molecules have shown promising results. The incapacity to achieve the wanted levels of target inhibition was the major shortcoming of the clinical trials. Yet, the use of higher doses is not possible due to toxicity problems, which led to the development of combinations of drugs targeting different pathways. Furthermore, it is more advisable to measure the outcome of the treatments in terms of CSCs behavior, by assessing capacity to metastasize and re-growth after removing the drug.

**FUTURE PERSPECTIVES**

The validation of potential gastric and colorectal CSCs biomarkers and their association with GC and CRC stage is imperative to understand patient prognosis and apply a more suitable therapy. The development of a robust therapy combining CSC targets with conventional chemotherapy could be the solution to overcome resistance to anti-cancer drugs and completely eliminate cancer. Considering these issues, it is crucial that future studies further explore the role of TFs and components of signaling pathways on cancer stemness in order to develop therapies that could eradicate CSCs.

**AUTHOR CONTRIBUTIONS**

All authors listed have made a substantial, direct and intellectual contribution to the work, and approved it for publication.

**FUNDING**

This work was supported by the FEDER – Fundo Europeu de Desenvolvimento Regional funds through the COMPETE 2020 – Operacional Programme for Competitiveness and Internationalisation (POCI), Portugal 2020, and by Portuguese funds through the FCT – Fundação para a Ciência e a Tecnologia/Ministério da Ciência, Tecnologia e Inovação in the framework of the project “Institute for Research and Innovation in Health Sciences” (POCI-01-0145-FEDER-007274); projects POCI-01-0145-FEDER-029017 and POCI-01-0145-FEDER-016390 funded by FCT. DP acknowledges FCT for financial support through a Ph.D. fellowship (SFRH/BD/146186/2019).

**REFERENCES**

Abbasian, M., Mousavi, E., Arab-Bafraani, Z., and Sahelkar, A. (2019). The most reliable surface marker for the identification of colorectal cancer stem-like cells: a systematic review and meta-analysis. *J. Cell Physiol.* 234, 8192–8202. doi: 10.1002/jcp.27619

Abetov, D., Mustapova, Z., Saliev, T., Bulanin, D., Batyrbekov, K., and Gilmian, C. P. (2015). Novel small molecule inhibitors of cancer stem cell signaling pathways. *Cell Stem Cell Rev.* 11, 909–918. doi: 10.1007/s12105-015-9612-x

Akbari, M., Shomali, N., Faraji, A., Shanehbandi, D., Asadi, M., Mokhtarzadeh, A., et al. (2020). CD133: an emerging prognostic factor and therapeutic target in colorectal cancer. *Cell Biol. Int.* 44, 368–380. doi: 10.1002/cbin.11243

Al-Batran, S. E., Ducreux, M., and Ohtsu, A. (2012). mTOR as a therapeutic target for the maintenance of gastric and colorectal CSCs phenotype. *Frontiers in Cell and Developmental Biology* [www.frontiersin.org](http://www.frontiersin.org). doi: 10.1083/jcb.200704152

Basu, S., Haase, G., and Ben-Ze’ev, A. (2016). Wnt signaling in cancer stem cells and colon cancer metastasis. *F1000Res.* 5:F1000 Faculty Rev-699. doi: 10.12688/f1000research.7579.1

Behrens, J., von Kries, J. P., Kuhl, M., Bruhn, L., Wedlich, D., Grosschedl, R., et al. (1996). Functional interaction of beta-catenin with the transcription factor LEF-1. *Nature* 382, 638–642. doi: 10.1038/382638a0

Bekaii-Saab, T., and El-Rayes, B. (2017). Identifying and targeting cancer stem cells in the treatment of gastric cancer. Cancer 123, 1303–1312. doi: 10.1002/cncr.30538

Bendell, J. C., Hubbard, J. M., O’Neil, B. H., Jonker, D. J., Starodub, A., Peyton, J. D., et al. (2017). Phase Ib/II study of cancer stemness inhibitor napabucasin (BBI-608) in combination with FOLFIRI + bevacizumab (bev) in metastatic colorectal cancer (mCRC) patients (pts). *J. Clin. Oncol.* 35, 3529–3529. doi: 10.1200/JCO.2017.35.15_suppl.3529

Berlin, J., Bendell, J. C., Hart, L. L., Firdaus, I., Gore, I., Hermann, R. C., et al. (2013). A randomized phase II trial of vismodegib versus placebo in patients with previously untreated metastatic colorectal cancer. *Clin. Cancer Res.* 19, 258–267. doi: 10.1186/1756-9549-12-1800

Boesch, M., Spizoo, G., and Seebert, A. (2018). Concise review: aggressive colorectal cancer: role of epithelial cell adhesion molecule in cancer stem cells and epithelial-to-mesenchymal transition. *Stem Cells Transl. Med.* 7, 495–501. doi: 10.1002.stem.17-0289

Bredt, J., Jung, A., Spaderna, S., Hlubek, F., and Kirchner, T. (2005). Opinion: migrating cancer stem cells - an integrated concept of malignant tumor progression. *Nat. Rev. Cancer* 5, 744–749. doi: 10.1038/nrc1694

Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R. L., Torre, L. A., and Jemal, A. (2018). Global cancer statistics 2018: GLOBOCAN estimates of incidence and

---

Pádua et al. | June 2020 | Volume 8 | Article 442 | 16 | Frontiers in Cell and Developmental Biology | www.frontiersin.org | 162020
Fang, D. P., Zhang, C. C., Gu, Y., Jani, J. P., Cao, J., Tsaparikos, K., et al. (2013). Antitumor efficacy of the dual PI3K/mTOR inhibitor PF-04691502 in a Human Xenograft tumor model derived from colorectal cancer stem cells harboring a PIK3CA mutation. PLoS One 8:e67258. doi: 10.1371/journal.pone.0067258
Farkona, S., Diamandis, E. P., and Blasutig, I. M. (2016). Cancer immunotherapy: the beginning of the end of cancer? BMC Med. 14:73. doi: 10.1186/s12196-016-0623-5
Finger, D. C., Richardson, C. J., Tee, A. R., Cheatham, L., Tsou, C., and Blenis, J. (2004). mTOR controls cell cycle progression through its cell growth effectors S6K1 and 4E-BP1/eukaryotic translation initiation factor 4E. Mol. Cell. Biol. 24, 200–216. doi: 10.1128/mcb.24.1.200-216.2004
Forghanifard, M. M., Moghibi, M., Raeesossadati, R., Tavassoli, A., Mallak, A. I., Boroumand-Noughabi, S., et al. (2013). Role of SALL4 in the progression and metastasis of colorectal cancer. J. Biomed. Sci. 20:6. doi: 10.1186/1423-7283-20-7-20-6
Francipane, M. G., and Lagasse, E. (2013). Selective targeting of human colon cancer stem-like cells by the mTOR inhibitor Torin-1. Oncotarget 4, 1948–1962. doi: 10.18632/oncotarget.1310
Fujita, T., Chiwaki, F., Takahashi, R. U., Aoyagi, K., Yanagihara, K., Nishimura, T., et al. (2013). CD49d(high) cells retain sphere-forming and tumor-initiating activities in human gastric tumors. PLoS One 8:e72438. doi: 10.1371/journal.pone.0072438
Hashimoto, K., Aoyagi, K., Isobe, T., Koihiji, K., and Shirouzu, K. (2014). Expression of CD133 in the cytoplasm is associated with cancer progression and poor prognosis in gastric cancer. Cancer Sci. 105, 3231–3233. doi: 10.1111/csc.12680
Hori, A., Nakatsuru, S., Miyoshi, Y., Ichii, S., Nagase, H., Kato, Y., et al. (1992). The APC gene, responsible for familial adenomatous polyposis, is mutated in human gastric cancer. Cancer Res. 52, 3231–3233.
Horst, D., Kriegel, L., Engel, J., Kirchner, T., and Jung, A. (2009). Prognostic significance of the cancer stem cell markers CD133, CD44, and CD166 in colorectal cancer. Cancer Invest. 27, 844–850. doi: 10.1080/07357900802493957
Ishigami, S., Arigami, T., Uenosono, Y., Okumura, H., Kurahara, H., Uchikado, Y., et al. (2016). Cancer stem cells may contribute to the difficulty in treating colorectal cancer. Cancer Sci. 107, 1580–1590. doi: 10.1111/csc.13002
Ishimoto, T., Sawayama, H., Sugihara, H., and Baba, H. (2014). Interaction between CD133 and Sox17 is involved in its regulation in cancer. Sci. Rep. 4, 1580–1590. doi: 10.1038/srep04158
Ishimoto, T., Sawayama, H., Sugihara, H., and Baba, H. (2014). Interaction between CD133 and Sox17 is involved in its regulation in cancer. Sci. Rep. 4, 1580–1590. doi: 10.1038/srep04158
Iwashita, M., iPodi, K., Moustakas, J., and Kyriakis, J. M. (2009). Identification of selective inhibitors of cancer stem cells by high-throughput screening. Cell 138, 645–659. doi: 10.1016/j.cell.2009.06.034
Ishimoto, T., Sawayama, H., Sugihara, H., and Baba, H. (2014). Interaction between CD133 and Sox17 is involved in its regulation in cancer. Sci. Rep. 4, 1580–1590. doi: 10.1038/srep04158
Iwashita, M., iPodi, K., Moustakas, J., and Kyriakis, J. M. (2009). Identification of selective inhibitors of cancer stem cells by high-throughput screening. Cell 138, 645–659. doi: 10.1016/j.cell.2009.06.034
Jiang, X., Xu, S., Liu, Z., Tao, Y., and Li, L. (2016). Decreased KLF4 expression may correlate with poor clinical outcome in human gastric cancer. Oncol. Lett. 13, 819–826. doi: 10.3892/ol.2016.5499
Jiang, X., Xu, S., Liu, Z., Tao, Y., and Li, L. (2016). Decreased KLF4 expression may correlate with poor clinical outcome in human gastric cancer. Oncol. Lett. 13, 819–826. doi: 10.3892/ol.2016.5499
Han, S.-M., Han, S.-H., Cho, H. J., Lee, M. S., Kim, H. J., et al. (1999). c-Myc expression is related with cell proliferation and associated with poor clinical outcome in human gastric cancer. J. Korean Med. Sci. 14, 526–530. doi: 10.3346/jkms.1999.14.5.526
Han, S.-M., Han, S.-H., Cho, H. J., Lee, M. S., Kim, H. J., et al. (1999). c-Myc expression is related with cell proliferation and associated with poor clinical outcome in human gastric cancer. J. Korean Med. Sci. 14, 526–530. doi: 10.3346/jkms.1999.14.5.526
Iv Santaliz-Ruiz, L. E., Xie, X., Old, M., Teknos, T. N., and Pan, Q. (2014). Emerging role of nanog in tumorigenesis and cancer stem cells. *Int. J. Cancer* 135, 2741–2748. doi: 10.1002/ijc.26690

Jackstadt, R., van Hoof, S. R., Leach, J. D., Cortes-Lavaud, X., Lobuisi, J. O., Ridgway, R. A., et al. (2019). Epithelial NOTCH signaling rewires the tumor microenvironment of colorectal cancer to drive poor-prognosis subtypes and metastasis. *Cancer Cell* 36, 219.e–216.e. doi: 10.1016/j.ccell.2019.08.003

Jansen, K. P., Alberici, P., Fiši, H., Gaspar, C., Breukel, C., Franken, P., et al. (2006). APC and oncogenic KRAS are synergistic in enhancing Wnt signaling in intestinal tumor formation and progression. *Gastroenterology* 131, 1096–1109. doi: 10.1053/j.gastro.2006.08.011

Javier, B. M., Yaeger, R., Wang, L., Sanchez-Vega, F., Zehir, A., Middha, S., Jackstadt, R., van Hooff, S. R., Leach, J. D., Cortes-Lavaud, X., Lohuis, J. O., Iv Santaliz-Ruiz, L. E., Xie, X., Old, M., Teknos, T. N., and Pan, Q. (2014). Prognostic impact of CD44-positive cancer stem-like cells at the invasive front of gastric cancer. *Br. J. Cancer* 116, 186–194. doi: 10.1038/bjc.2014.101

Kolligs, F. T., Bommer, G., and Goke, B. (2002). Wnt/beta-catenin/tcf signaling: a critical pathway in gastrointestinal tumorigenesis. *Digestion* 66, 131–144. doi: 10.1159/000066755

Krizhanovsky, V., and Lowe, S. W. (2009). Stem cells: the promises and perils of p53. *Nature* 460, 1085–1086. doi: 10.1038/4601085a

Kuipers, E. J., Grady, W. M., Lieberman, D., Seufferlein, T., Sung, J. J., Boelens, P. G., et al. (2015). Colorectal cancer. *Nat. Rev. Dis. Primers* 1, 2956. doi: 10.1038/nrdp.2015.65

Labianca, R., Nordlinger, B., Beretta, G. D., Mosconi, S., Mandalà, M., Cervantes, A., et al. (2013). Early colon cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. *Ann. Oncol.* 24(Suppl. 6), vi64–w72. doi: 10.1093/annonc/mdt354

Lang, S. A., Gaumann, A., Koelbl, G. E., Seidel, U., Bataille, F., Klein, D., et al. (2007). Mammalian target of rapamycin is activated in human gastric cancer and serves as a target for therapy in an experimental model. *Int. J. Cancer* 120, 1803–1810. doi: 10.1002/ijc.22442

Lau, E. Y.-T., Ho, N. P.-Y., and Lee, T. K.-W. (2017). Cancer stem cells and their microenvironment: biology and therapeutic implications. *Stem Cells Int.* 2017:714190. doi: 10.1155/2017/714190

Lee, H. H., Seo, K. J., An, C. H., Kim, J. S., and Jeon, H. M. (2012). CD133 expression is correlated with the degree of differentiation of gastric cancer. *Gastric Cancer* 15, 440–450. doi: 10.1007/s10120-012-0140-y

Lee, J., Li, W., He, X., Zhang, J., Jiang, F., and Chen, Z. (2016). Lgr5 expression is a valuable prognostic factor for colorectal cancer: evidence from a meta-analysis. *BMJ Cancer* 16:12. doi: 10.1186/s12885-015-1985-3

Li, M. X., Wang, Q., Wang, B., Yan, D. W., Tang, H. M., Peng, Z. H., et al. (2012). Novel expression patterns of PIK3/Akt/mTOR signaling pathway components in colorectal cancer. *J. Am. Coll. Surg.* 210, 767–776. doi: 10.1016/j.jamcollsurg.2009.12.008

Leng, Z., Tao, K., Xia, Q., Tan, J., Yue, Z., Chen, J., et al. (2013). Kruppel-like factor 4 acts as an oncogene in colon cancer stem cell-enriched spheroid cells. *PLoS One* 8:e60682. doi: 10.1371/journal.pone.006082

Leng, Z., Xia, Q., Chen, J., Li, Y., Xu, J., Zhao, E., et al. (2018). Lgr5+CD44+EpCAM+ strictly defines cancer stem cells in human colorectal cancer. *Cell. Physiol. Biochem.* 46, 860–872. doi: 10.1159/000488743

Lin, T., Ding, Y.-Q., and Li, J.-M. (2012). Overexpression of Nanog protein is related to advanced clinical stage and poor prognosis in patients with gastric cancer. *Zhonghua Wei Chang Wai Ke Za Zhi* 42, 646–651. doi: 10.1007/s12032-011-9860-9

Lin, T., Ding, Y.-Q., and Li, J.-M. (2012). Overexpression of Nanog protein is associated with poor prognosis in gastric adenocarcinoma. *Med. Oncol.* 29, 878–885. doi: 10.1007/s12032-011-9860-9

Li, Y., Rogoff, H. A., Keates, S., Gao, Y., Murikupudi, S., Mikule, K., et al. (2015). Suppression of cancer relapse and metastasis by inhibiting cancer stemness. *Proc. Natl. Acad. Sci. U.S.A.* 112, 1839–1844. doi: 10.1073/pnas.1421711112

Lin, L., Liu, A., Peng, Z., Lin, H. J., Li, P. K., Li, C., et al. (2011). ST43 is necessary for proliferation and survival in colon cancer-initiating cells. *Cancer Res.* 71, 7226–7237. doi: 10.1158/0008-5472.CAN-10-4660

Lin, Q., Lai, R., Chirieac, L. R., Li, C., Thomazy, V. A., Grammatikakis, I., et al. (2005). Constitutive activation of JAK3/STAT3 in colon carcinoma tumors and cell lines: inhibition of JAK3/STAT3 signaling induces apoptosis and cell cycle arrest of colon carcinoma cells. *Am. J. Pathol.* 167, 969–980. doi: 10.1016/j.ajpath.2004.06.018

Kang, H., An, H. J., Song, J. Y., Kim, T. H., Heo, J. H., Ahn, D. H., et al. (2012). Notch3 and Jagged2 contribute to gastric cancer development and to glandular differentiation associated with MUC2 and MUC5AC expression. *Histopathology* 61, 576–586. doi: 10.1111/j.1365-2559.2012.04274.x

Karnacki, J., Joseph, J., Kurniali, P. C., Al-Janadi, A., and Hrinczenko, B. (2017). Adjuvant chemotherapy for stage II colorectal cancer: a clinical dilemma. *J. Oncol. Pract.* 13, 233–241. doi: 10.1200/jop.2016.017210

Kim, E. J., Shin, H.-K., and Park, J. H. Y. (2005). Genistein inhibits insulin-like growth factor-1 receptor signaling in HT-29 human colon cancer cells: a possible mechanism of the growth inhibitory effect of Genistein. *J. Med. Food* 8, 431–438. doi: 10.1189/jmf.2005.8.431

Kim, H. R., Lim, H. J., Lee, H. J., Park, J. H., and Park, S. G. (2019). Evaluation and clinical significance of jagged-1-activated notch signaling by APEX1 in colorectal cancer. *Anticancer Res.* 39, 6097–6105. doi: 10.21873/anticancer.13817

Kim, Y., Joo, K. M., Jin, J., and Nam, D.-H. (2009). Cancer stem cells and their mechanism of chemoresistance. *Int. J. Stem Cells* 2, 109–114. doi: 10.15283/jsc.2009.2.109

Kemper, K., Prasetyanti, P. R., De Lauff, W., Rodenrmond, H., Clevers, H., and Medema, J. P. (2012). Monoclonal antibodies against Lgr5 identify human colorectal cancer stem cells. *Stem Cells* 30(2), 2378–2386. doi: 10.1002/stem.1233.
Menon, S., Shin, S., and Dy, G. (2016). Advances in cancer immunotherapy in solid tumors. *Cancers* **8**:1106. doi: 10.3390/cancers8120106

Mesquita, P., Freire, A. F., Lopes, N., Gomes, R., Azevedo, D., Barros, R., et al. (2019). Expression and clinical relevance of SOX9 in gastric cancer. *Dis. Markers* 2019:2867021. doi: 10.1155/2019/2867021

Mihl, P., and Downdward, J. (2005). Mechanisms of disease: PI3K/AKT signaling in gastrointestinal cancers. *Z. Gastroenterol.* **43**:1313.

Miyoshi, N., Fujino, S., Ohue, M., Yatsui, M., Takahashi, Y., Sugimura, K., et al. (2018). The POU5F1 gene expression in colorectal cancer: a novel prognostic marker. *Surg. Today* **48**:709–715. doi: 10.1007/s10595-018-1644-9

Miyoshi, N., Ishii, H., Nagai, K., Hoshino, H., Mimori, K., Tanaka, F., et al. (2010). Defined factors induce reprogramming of gastrointestinal cancer cells. *Proc. Natl. Acad. Sci. U.S.A.* **107**:40–45. doi: 10.1073/pnas.0912407107

Mohamed, S. Y., Kaf, R. M., Ahmed, M. M., Elwan, A., Ashour, H. R., and Ibrahim, A. (2019). The prognostic value of cancer stem cell markers (Notch1, ALDH1, and CD34) in primary colorectal carcinoma. *J. Gastrointest. Cancer* **50**:824–837. doi: 10.1007/s12028-019-0156-6

Müller, S., Cañete, T., Azevedo, V., and Rodríguez, R. (2017). Targeting cancer stem cells with small molecules. *Isr. J. Chem.* **57**:239–250. doi: 10.1002/iijc.201601009

Munro, M. J., Wickremesekera, S. K., Peng, L., Tan, S. T., and Iitinteang, T. (2018). Cancer stem cells in colorectal cancer: a review. *J. Clin. Pathol.* **71**:110–116. doi: 10.1136/jclinpath-2017-204739

Murayama, T., Inokuchi, M., Takagi, Y., Yamada, H., Kojima, K., Kumagi, J., et al. (2009). Relation between outcomes and localisation of p-mTOR expression in gastric cancer. *Br. J. Cancer* **100**:782–788. doi: 10.1038/sj.bjc.6605913

Muzny, D. M., Bainbridge, M. N., Chang, K., Duh, H. H., Drummond, J. A., et al. (2012). Comprehensive molecular characterization of human colon and rectal cancer. *Nature* **487**:330–337. doi: 10.1038/nature11252

Mylant, K. B., Cammareri, P., McGhee, E. J., Ridgway, R. A., Huels, D. J., Cordero, J. B., et al. (2013). ROS production and NF-κB activation triggered by RAC1 facilitate WT1-driven intestinal stem cell proliferation and colorectal cancer initiation. *Cell Stem Cell* **12**:761–773. doi: 10.1016/j.stem.2013.04.006

Nakatani, S., Yanagisawa, A., Fukurawa, Y., Ishii, S., Kato, Y., Nakamura, Y., et al. (1993). Somatic mutations of the APC gene in preneoplastic lesions of the stomach. *Hum. Mol. Genet.* **2**:1463–1465. doi: 10.1093/hmg/2.9.1463

Narayankutty, A. (2019). PI3K/ Akt/ mTOR pathway as a therapeutic target for colorectal cancer: a review of preclinical and clinical evidence. *Curr. Drug Targets* **20**:1217–1226. doi: 10.21189/510450201669016123848

Neri, B., Pantaloo, P., Giromini, E., Grifoni, R., Paoletti, C., Rotella, V., et al. (2007). Oxaiplatin, 5-fluorouracil/leucovorin and epirubicin as first-line treatment in advanced gastric carcinoma: a phase II study. *Br. J. Cancer* **96**:1043–1046. doi: 10.1038/sj.bjc.6603644

Niedzwiecki, D., Bertagnolli, M. M., Warren, R. S., Compton, C. C., Kemeny, N. E., Benson, A. B., et al. (2011). Documenting the natural history of patients with resected stage II adenocarcinoma of the colon after random assignment to adjuvant treatment with edrecolomb or observation: results from CALGB 9581. *J. Clin. Oncol.* **29**:3146–3152. doi: 10.1200/jco.2010.32.5357

Nosrati, A., Naghshvar, F., and Khanari, S. (2014). Cancer stem cell markers CD44, ALDH1, and CD44 in primary colorectal carcinoma. *Cancer Sci.* **105**:1301–1315. doi: 10.1111/j.1349-7006.2007.00643.x

O'Brien, C. A., Pollett, A., Gallinger, S., and Dick, J. E. (2007). The POU5F1 gene expression in colorectal cancer: a novel prognostic marker. *Br. Med. Bull.* **82**:43–67. doi: 10.1093/bmbld/72.3.85

Ohkuma, M., Haraguchi, N., Ishii, H., Mimori, K., Tanaka, F., et al. (2013). ROS production and NF-κB activation triggered by RAC1 facilitate WT1-driven intestinal stem cell proliferation and colorectal cancer initiation. *Cell Stem Cell* **12**:761–773. doi: 10.1016/j.stem.2013.04.006

Ong, C. W., Kim, L. G., Kong, H. H., Low, L. Y., Iacopetta, B., Soong, R., et al. (2010). CD71 expression predicts for non-response to chemotherapy in colorectal cancer. *Med. Oncol.* **27**:450–457. doi: 10.1007/s12032-010-9019-9

Ori, C. H., Ivanova, T., Wu, J., Lee, M., Tan, I. B., Tao, J., et al. (2009). Oncogenic pathway combinations predict clinical prognosis in gastric cancer. *PLoS Genet.* **5**:e1000676. doi: 10.1371/journal.pgen.1000676

Paiva, C., Perrault, A., Gallinger, S., and Dick, J. E. (2007). A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. *Nature* **445**:106–110. doi: 10.1038/nature05372

Okumura, M., Haraguchi, N., Ishii, H., Mimori, K., Tanaka, F., Kim, H. M., et al. (2012). Absence of CD71 transferrin receptor characterizes human gastric adenocarcinomas. *Carcinogenesis* **26**:1698–1705. doi: 10.1093/carcin/bgl130

Ogawa, M., Yui, Y., Morishita, K., Kataoka, Y., Hamada, H., Kojima, K., et al. (2009). CD71 expression predicts for non-response to chemotherapy in colorectal cancer. *Med. Oncol.* **26**:450–457. doi: 10.1007/s12032-009-9019-9

Onimaru, H., Oishiya, K., Konishi, H., Mimori, K., Tanaka, F., et al. (2011). Absence of CD71 transferrin receptor characterizes human gastric adenocarcinomas. *Carcinogenesis* **26**:1698–1705. doi: 10.1093/carcin/bgl130

Ogawa, M., Yui, Y., Morishita, K., Kataoka, Y., Hamada, H., Kojima, K., et al. (2009). CD71 expression predicts for non-response to chemotherapy in colorectal cancer. *Med. Oncol.* **26**:450–457. doi: 10.1007/s12032-009-9019-9

Ogawa, M., Yui, Y., Morishita, K., Kataoka, Y., Hamada, H., Kojima, K., et al. (2009). CD71 expression predicts for non-response to chemotherapy in colorectal cancer. *Med. Oncol.* **26**:450–457. doi: 10.1007/s12032-009-9019-9
Pintova, S., Dharmupari, S., Moshier, E., Zubizarreta, N., Ang, C., and Holcombe, R. F. (2014). Tackling the cancer stem cells -

Patel, S., Alam, A., Pant, R., and Chattopadhyay, S. (2019). Wnt signaling and its therapeutic implications in cancer treatment. Stem Cells Int. 2018:5416923. doi: 10.1155/2018/5416923

Pintova, S., Dharmupari, S., Mosheri, E., Zubizarreta, N., Ang, C., and Holcombe, R. F. (2019). Genistein combined with FOLFOX or FOLFOX–Bevacizumab for the treatment of metastatic colorectal cancer: phase II/II pilot study. Cancer Chemother. Pharmacol. 84, 591–598. doi: 10.1007/s00280-019-03886-3

Prévestol, C., and Blache, P. (2017). The dose-dependent effect of SOX9 and its regulation of cancer stem cell microenvironment. Curr. Stem Cell Res. Ther. 7, 197–216. doi: 10.2174/157488812799859938

Quante, M., Varga, J., Wang, T. C., and Greten, F. R. (2013). The gastrointestinal tumor microenvironment. Gastroenterology 145, 63–78. doi: 10.1053/j.gastro.2013.03.052

Robertson, J. H., Yang, S. Y., Winslet, M. C., and Seifalian, A. M. (2009). Functional AKT, as second-line therapy for advanced gastric and gastroesophageal junction tumor microenvironment. Nat. Rev. Drug Discov. 2013.03.052

Sonbol, M. B., Ahn, D. H., and Bekaii-Saab, T. (2019). Therapeutic targeting of cancer stem cells in gastrointestinal malignancies. Biomedicines 7:17. doi: 10.3390/biomedicines7010017

Sonbol, M. B., Ahn, D. H., and Bekaii-Saab, T. (2019). Therapeutic targeting of cancer stem cells in gastrointestinal malignancies. Biomedicines 7:17. doi: 10.3390/biomedicines7010017

Smyth, E. C., Verheji, M., Allum, W., Cunningham, D., Cervantes, A., Arnold, D., et al. (2016). Gastric cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 27(Suppl._5), v38–v49. doi: 10.1093/annonc/mdw350

Sobol, M. B., Ahn, D. H., and Bekaii-Saab, T. (2019). Therapeutic targeting of cancer stem cells in gastrointestinal malignancies. Biomedicines 7:17. doi: 10.3390/biomedicines7010017

Song, Z., Wu, Y., Yang, J., Yang, D., and Fang, X. (2017). Progress in the treatment of advanced gastric cancer. Tumor Biol. 39:104283171774626. doi: 10.1177/102738081774626

Strosberg, J. R., Yeatman, T., Weber, J., Coppola, D., Schell, M. J., Han, G., et al. (2012). A phase II study of RO4929097 in metastatic colorectal cancer. Eur. J. Cancer 48, 997–1003. doi: 10.1016/j.ejca.2012.02.056

Sun, S.-J., Chow, N.-H., Kung, M.-L., Hung, T.-C., and Chang, K.-L. (2003). Effects of soy isolflavones on apoptosis induction and G2-M arrest in human hepatoma cells involvement of caspase-3 activation, Bcl-2 and Bcl- XL downregulation, and Cdk2 kinase activity. Nutr. Cancer 45, 113–123. doi: 10.1080/01635580390202902

Takahashi, K., and Yamanaka, S. (2006). Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 126, 663–676. doi: 10.1016/j.cell.2006.07.024

Tai, M.-H., Chang, C.-C., Olson, L. K., and Trosko, J. E. (2005). Oct4 expression and its methylation status in gastric cancer. Virchows Arch. 460, 271–279. doi: 10.1007/s00428-012-1201-7

Takeda, K., Mizushima, T., Yokoyama, Y., Hirose, H., Wu, X., Qian, Y., et al. (2018). Sox2 is associated with cancer stem-like properties in colorectal cancer. Sci. Rep. 8:17639.

Takai, S., Okumura, T., Tu, S., Wang, S. S. W., Shibata, W., Vigneshwaran, R., et al. (2009). Identification of gastric cancer stem cells using the cell surface marker CD44. Stem Cells 27, 1006–1020. doi: 10.1002/stem.2030

Takebe, N., Harris, P. L., Warren, R. Q., and Ivy, S. P. (2011). Targeting cancer stem cells by inhibiting Wnt, Notch, and Hedgehog pathways. Nat. Rev. Clin. Oncol. 8, 97–106. doi: 10.1038/nrclinonc.2010.196

Tan, T., Zhang, Y., Wang, S., Zhou, J., and Xu, S. (2012). Sox2 enhances the tumorigenicity and chemoresistance of cancer stem-like cells derived from gastric cancer. J. Biomed. Res. 26, 336–345. doi: 10.7555/JBR.26.20120045

Tolcher, A. W., Messersmith, W. A., Mikulski, S. M., Papadopoulos, K. P., Kwak, E. L., Gibson, D. G., et al. (2012). Phase I Study of RO4929097, a gamma
secretase inhibitor of notch signaling, in patients with refractory metastatic or locally advanced solid tumors. J. Clin. Oncol. 30, 2348–2353. doi: 10.1200/jco.2011.36.2828

Usui, T., Sakurai, M., Umata, K., Elbadawy, M., Ohama, T., Yamawaki, H., et al. (2018). Hedgehog signals mediate anti-cancer drug resistance in three-dimensional primary colorectal cancer organoid culture. Int. J. Mol. Sci. 19:1908. doi: 10.3390/ijms19041908

Vadde, R., Vemula, S., Jinka, R., Merchant, N., Bramhchari, P. V., and Nagaraju, G. P. (2017). Role of hypoxia-inducible factors (HIF) in the maintenance of stemness and malignancy of colorectal cancer. Crit. Rev. Oncol. Hematol. 113, 22–27. doi: 10.1016/j.critrevonc.2017.02.005

Vatopoulos, A. G., Kostakis, I. D., Koutsilieris, M., and Papavassiliou, A. G. (2012). Colorectal cancer stem cells. Stem Cells 30, 363–371. doi: 10.1002/stem.1031

van der Heijden, M., and Vermeulen, L. (2019). Stem cells in homeostasis and cancer of the gut. Mol. Cancer 18:66. doi: 10.1186/s12943-019-0962-z

Varnat, F., Duquet, A., Malerba, M., Zhinden, M., Mas, C., Gervaz, P., et al. (2009). Human colon cancer epithelial cells harbour active HEDGEHOG-GLI signalling that is essential for tumour growth, recurrence, metastasis and stem cell survival and expansion. EMBO Mol. Med. 1, 338–351. doi: 10.1002/emmm.200900039

Venkatesh, V., Nataraj, R., Thangaraj, G. S., Karthikeyan, M., Gnanasekaran, A., Kaginelli, S. B., et al. (2018). Targeting Notch signalling pathway of cancer stem cells. Stem Cell Investig. 5:5. doi: 10.21037/sci.2018.02.02

Vermeulen, L., De Sousa, E., Melo, F., van der Heijden, M., Cameron, K. de Jong, J. H., et al. (2010). Wnt activity defines cancer stem cells and is regulated by the microenvironment. Nat. Cell Biol. 12, 468–476. doi: 10.1038/ncb2048

Vermeulen, L., Todaro, M., de Sousa Mello, F., Sprick, M. R., Kemper, K., Perez Varela, M., et al. (2013). Multicenter phase II study of tivozanib (AV-951) and everolimus in patients with gastric cancer. Biochim. Biophys. Acta 1813, 258–267. doi: 10.1016/j.bbcan.2010.06.060

Yuan, X., Zhang, X., Zhang, P., Shi, H., et al. (2016). SALL4 overexpression promotes gastric cancer cell proliferation and migration and induces drug resistance by combining with the AKT-mTOR pathway. Biomed. Pharmacother. 111, 993–1004. doi: 10.1016/j.biopha.2019.01.018

Yu, H., Kortylewski, M., and Pardoll, D. (2007). Crosstalk between cancer and immunity: a leading role for STAT3. Clin. Cancer Res. 13, 416–426. doi: 10.1158/1078-0432.CCR-06-0095

Yu, G., Wang, J., Chen, Y., Wang, X., Pan, J., Li, G., et al. (2009). Overexpression of GLI1 promotes gastric cancer cell proliferation and migration and induces drug resistance by combining with the AKT-mTOR pathway. Biomed. Pharmacother. 63, 542–548. doi: 10.1016/j.biopha.2008.11.020

Yu, H., Pardoll, D., and Jove, R. (2009). STATs in cancer inflammation and immunity: a leading role for STAT3. Nat. Rev. Cancer 9, 798–809. doi: 10.1038/nrc2734

Zhang, C., Li, C., He, F., Cai, Y., and Yang, H. (2011). Identification of CD44+CD24+ gastric cancer stem cells. J. Cancer Res. Clin. Oncol. 137, 1679–1686. doi: 10.1007/s00432-011-1038-5

Zhang, H., and Xue, Y. (2008). Wnt pathway is involved in advanced gastric carcinoma. Hepatogastroenterology 55, 1126–1130.
Zhang, H. L., Wang, P., Lu, M. Z., Zhang, S. D., and Zheng, L. (2019). c-Myc maintains the self-renewal and chemoresistance properties of colon cancer stem cells. Oncol. Lett. 17, 4487–4493. doi: 10.3892/ol.2019.10081

Zhang, J., Espinoza, L. A., Kinders, R. J., Lawrence, S. M., Pfister, T. D., Zhou, M., et al. (2013). NANOG modulates stemness in human colorectal cancer. Oncogene 32, 4397–4405. doi: 10.1038/onc.2012.461

Zhang, J., Tam, W. L., Tong, G. Q., Wu, Q., Chan, H. Y., Soh, B. S., et al. (2006). Sall4 modulates embryonic stem cell pluripotency and early embryonic development by the transcriptional regulation of Pou5f1. Nat. Cell Biol. 8, 1114–1123. doi: 10.1038/ncb1481

Zhang, L., Xu, Z., Xu, X., Zhang, B., Wu, H., Wang, M., et al. (2014). SALL4, a novel marker for human gastric carcinogenesis and metastasis. Oncogene 33, 5491–5500. doi: 10.1038/onc.2013.495

Zhang, N., Zhang, J., Wang, Z. W., Zha, L., and Huang, Z. (2012). Altered expression of Krüppel-like factor 4 and β-catenin in human gastric cancer. Oncol. Lett. 3, 1017–1022. doi: 10.3892/ol.2012.619

Zhao, R., Liu, Z., Xu, W., Song, L., Ren, H., Ou, Y., et al. (2020). Helicobacter pylori infection leads to KLF4 inactivation in gastric cancer through a TET1-mediated DNA methylation mechanism. Cancer Med. 9, 2551–2563. doi: 10.1002/cam4.2892

Zhao, R., Li, Y., and Zhang, X. (2017). Stemness-related markers in cancer. Cancer Transl. Med. 3, 87–95. doi: 10.4103/ctm.ctm_69_16

Zhi, Q. M., Chen, X. H., Ji, J., Zhang, J. N., Li, J. F., Cai, Q., et al. (2011). Salinomycin can effectively kill ALDH(high) stem-like cells on gastric cancer. Biomed. Pharmacother. 65, 509–515. doi: 10.1016/j.biopha.2011.06.006

Zhao, Y., Xia, L., Wang, H., Oyang, L., Su, M., Liu, Q., et al. (2017). Cancer stem cells in progression of colorectal cancer. Oncotarget 9, 33403–33415. doi: 10.18632/oncotarget.23607

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.